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ABSTRACT
The supply of nutrients and the removal of waste products play a major role in
tissue engineering. From all the nutrients necessary for cells seeded on scaffolds for tissue
regeneration, oxygen is the limiting component due to its low solubility in culture media
while cells consume five to six moles of oxygen for every mole of monosaccharide. The
aim of the present work was to develop different strategies to improve the supply of
oxygen to human coronary artery smooth muscle cells (HCASMC) seeded on three
dimensional (3D) porous biostable polyurethane scaffolds. As a springboard for the study,
the measured value of oxygen diffusivity through porous polyurethane scaffolds,
fabricated by using pressure differential/particulate leaching technique, was used to
screen the best polymer concentration. Scaffolds fabricated form 15 wt% polymer
concentration not only had higher oxygen diffusivity but also have better pore
interconnectivity as shown by SEM image analysis. Moreover a convective mass transfer
approach showed an improvement in the infiltration of HCASMCs into the 3D scaffolds.
An oxygen carrier molecule, perfluorodecalin (PFD), was found to improve dissolved
oxygen concentration in culture media. PFD was shown to be not only non-toxic to
HCASMC but also have no significant effect on the morphology of the HCASMCs.
Therefore, higher cell density and infiltration depth into the polyurethane scaffolds were
observed when HCASMCs were cultured in a media containing PFD. The final stage of
this work was to introduce an oxygen vector into the skeleton of polyurethane scaffolds.
For this reason, inert Zeolite Y particles were fluorinated and shown to enhance the
amount of dissolved oxygen when suspended in culture media. Fluorinated Zeolite (FZ)
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particles were then embedded into polyurethane scaffolds without modifying the porosity
and morphology of the 3D structures. Subsequently, higher cell density and infiltration
depths were observed when HCASMCs were cultured on FZ particles embedded
polyurethane scaffolds in contrast to bare polyurethane scaffolds. Taken together, these
data show three different but equally advantageous strategies of improving the supply of
oxygen to HCASMC seeded into the interstices of 3D polyurethane scaffolds.

Keywords: Tissue engineering, polyurethane scaffolds, vascular grafts, oxygen
diffusivity, vascular smooth muscle cells, oxygen carrier molecules, perfluorodecalin,
fluorinated Zeolite particles, cell proliferation, cell infiltration,
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CHAPTER
1
1 INTRODUCTION

1.1 Overview
Cardiovascular disease such as coronary artery occlusion is one of the leading causes of
death in both Western and non-Western societies.1 Conventional severe medically
refractory coronary and peripheral artery diseases treatment options such as the use of
autologous vessels and prosthetic grafts have suboptimal performances.2, 3 Over the past
15 years, the concept of vascular tissue engineering, representing an interdisciplinary
effort with considerable potential to treat vascular disease, has emerged to be a viable
treatment alternative.4 The strategies of in vitro tissue engineering are conceptually
simple and clinically appealing yet these have proven to be a formidable engineering task.
Despite rapid advances made in this field, success is still limited due to significant
knowledge gaps in our ability to regulate tissue formation. Within the context of
engineering, providing sufficient oxygen mass transport that is vital for cellular
metabolism is perhaps one of the unmet challenges to fabricate tissues of clinical
relevance.5,

6

It has long been known that the supply of oxygen and soluble nutrients

becomes critically limiting for the in vitro culture of 3D tissues.7 The consequence of
such a limitation is exemplified by early studies showing that cellular spheroids larger
than 1 mm in diameter generally contain a hypoxic and necrotic center surrounded by a
rim of viable cells.8 Similar observations beyond depths of 250 µm were reported for a

2
number of cells cultured on 3D scaffolds where a non-homogenous cell distribution is
reported.9-11 Because engineered blood vessels should be at least 500 µm in wall
thickness, mass transfer limitations represent one of the challenges to be addressed for
cell survival.

Unlike what is described above, in vivo mass transfer requirements are facilitated by
convective transport of hemoglobin-bound oxygen to tissues to the proximity of
capillaries. In most tissues, cells are no more than 100 µm from these capillaries allowing
sufficient oxygen to be delivered. The small diameter of capillaries (between 6 and 8 µm)
ensures a residence time long enough in tissues to permit the radial diffusion of chemical
species 12. Thus in vivo, cells are constantly perfused with the flowing blood through the
vasculature. At lower blood plasma concentrations of oxygen in tissues, oxygen
dissociates from hemoglobin and diffuses into tissues and cells. As the blood vessels
themselves are made up of cells, they too require sufficient oxygen and nutrients to
survive. Since the wall of the larger blood vessels is too thick to allow diffusion between
the blood stream and surrounding tissue of the wall, the adventitial layer of these vessels
contains small arteries called vasa vasorum that supply the smooth muscle cells and
fibroblasts within the media and adventitia their nutrient demand. Therefore mass transfer
within the vascular wall is facilitated by the diffusion of oxygen both from the lumen and
adventitial side.

3
1.2 Thesis Outline
In view of the above brief overview, the work presented in this thesis underscores the
importance of addressing oxygen mass transfer to design and fabricate vascular tissues of
clinical relevance. In Chapter 2, pertinent literature review is presented. Although the
open literature documented far exceeded those cited in this thesis, an effort was made to
focus on recent advances while equally acknowledging seminal works in the field. In
Chapter 3, scaffold fabrication, diffusion measurements, and some cell culture data are
presented. Chapters 4 and 5 describe two different approaches chosen to enhance oxygen
mass transfer in 3D cell cultures each with specific objectives.13,

14

Finally, the

significance, contributions, and limitations of the study are presented in Chapter 6.
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CHAPTER
2
2 LITERATURE REVIEW
Overview: This chapter provides background information on the physiology and diseases
of coronary arteries, surgical interventions and the need for and the challenges of tissueengineered vascular substitutes. Elements of vascular tissue engineering are presented
with a focus on the delivery of oxygen to engineered tissue constructs. It concludes with a
statement of study rationale and an outline of specific hypotheses and objectives of this
study.
2.1 Anatomy and Physiology of Coronary Arteries
Coronary arteries, which are the first to branch off from the ascending aorta, supply blood
to the heart muscle. Both the right and left coronary arteries extend from the aorta to the
heart walls supplying blood to the atria, ventricles, and septum of the heart. Coronary
arteries are composed of three concentric tunics (Figure 2.1). The tunica intima forms the
innermost lining composed of non-thrombogenic monolayer endothelial cells. By
secreting specific molecules such as nitric oxide, endothelial cells inhibit platelet
activation and prevent thrombus formation.1, 2 The tunica media is generally composed of
a dense population of concentrically organized smooth muscle cells and is separated from
the tunica intima by an internal elastic lamina.3 Under physiological conditions, smooth
muscle cells possess a quiescent contractile phenotype and control the dilation and
constriction of blood vessels thus regulating blood flow. Under pathological conditions,
smooth muscle cells convert to a synthetic and non-contractile phenotype. This synthetic
phenotype results in the proliferation and increased matrix production in the tunica media
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resulting vessel stenosis.4 The tunica adventitia (externa) forms the external layer and
contains a collagenous extracellular matrix and fibroblast cells. Ultimately, tissueengineered blood vessels should contain all of these layers for proper functionality.

Figure 2.1: Schematic representation and histology of coronary artery wall
structure.5
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2.2 Coronary Artery Diseases
Coronary artery disease is the most common form of heart disease. Atherosclerosis,
characterized by a progressive accumulation of lipids and fibrous elements in the lumen,
is a widely recognized inflammatory disease affecting the vasculature (Figure 2.2). The
early lesions of atherosclerosis consist of sub-endothelial accumulations of cholesterolengorged macrophages, called 'foam cells' which acts as preferred sites for lesion
formation.

Figure 2.2: Schematic representation of normal and diseased arteries.
With time, the lesions grow and will reach a point where the artery is so narrow that
blood flow becomes insufficient to supply the succeeding vessels leading to angina and
ischemia. The deprivation of blood results in oxygen deficiency in the myocardium, and
accumulation of carbon dioxide and lactic acid in the tissue.6 Unstable lesions with a thin
fibrous cap are highly susceptible to plaque rupture and erosion, exposing the necrotic
core and potentially leading to the formation of a thrombus. Thrombosis results in acute
artery occlusion leading to potentially fatal heart attack.7 In addition to inflammatory
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atherosclerotic lesions, congenital anomalies of the coronary artery are found in 1-2% of
the population.8-10

While the majority of these anomalies do not result in signs,

symptoms or complications, others such as coronary atresia, coronary hypoplasia, single
coronary artery and ectopic coronary origin are associated with serious events such as
myocardial infarction, cardiac arrhythmias, syncope, congestive heart failure and sudden
death.11-13

2.3 Surgical Intervention
In the early stages of the plaque build-up, a minimally invasive coronary balloon
angioplasty intervention technique is a preferred method to surgery for reopening
occluded atherosclerotic vessels. Following the intervention, stents are often deployed to
prevent elastic recoil of the vessel wall.14 However, for advanced atherosclerotic lesions,
coronary artery bypass grafting (CABG) is the only alternative. Autologous grafts remain
the primary choice for CABG because of their compliance, immune acceptance, and nonthrombogenicity. The most commonly used autograft is the saphenous vein (SV)
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but

the internal mammary artery and radial artery are also used.16 The extensive use of SV as
CABG is, in part, because it is surgically easier to access and harvest.17 However, its
performance is not sufficient in large due to the gradual deterioration when exposed to
high-pressure arterial sites leading to excessive dilation and also due to a combination of
intimal hyperplasia and accelerated atherosclerosis.18-22 Therefore, further surgical
revascularization is often required in about 10 years after the initial bypass surgery but the
availability of SV for second and third bypass surgery is a limitatition.23
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Even though the preferred bypass vascular substitute is the patient’s own arteries or veins,
they are generally inadequate or unsuitable for approximately one-third of patients

24, 25

suggesting the obvious need for alternative grafts.26 Prosthetic grafts have been developed
as an alternative to autografts and, the most commonly used materials are polyethylene
terephthalate (PET, Dacron®) and expanded polytetrafluoroethylene (ePTFE, Teflon®).
Dacron® and Teflon® have been used successfully in the replacing large arteries,
however, when the vessel diameter is under 5 mm, the clinical outcome is
disappointing.27,

28

The low patency of synthetic grafts in small diameter artery

reconstruction is due to lower blood flow velocities resulting from intimal hyperplasia at
the anastomotic site.13 The development of intimal hyperplasia is attributed to the
compliance mismatch between the graft and the native vessel, and the thrombogenecity of
the synthetic surface.29,

30

The difference in elasticity at the anastomotic site creates

turbulence in the blood flow and damages the endothelial lining, resulting in thrombus
formation and compliance mismatch as shown in Figure 2.3.31, 32 In order to avoid these
complications, patients having prosthetic grafts often require extensive anticoagulant
medications.

Figure 2.3: Schematic drawing showing the compliance mismatch between the
native tissue and a prosthetic graft leading to hemodynamic changes and thrombus
formation.

10
In addition to Dacron® and Teflon®, polyurethanes have been tested as vascular graft
materials due to improved compliance, thromboresistance, and reduced anastomotic
hyperplasia. 33 Polyurethanes are also reported to promote the ingrowth of living tissues
in and around the grafts potentially modifying the initial compliance of the graft.

34, 35

However, their clinical use as prosthetic grafts was limited due to their poor biostability.
36, 37

To overcome these issues, a newly developed polyurethane graft based on

polycarbonate soft segment showed improved resistance to biodegradation for a 3 year
period in a canine model.

38, 39

The presence of the polycarbonate soft segment is

responsible for the increased resistance to biodegradation in comparison to other soft
segments.

2.4 Engineered Vascular Tissues as Functionally Competent Conduits
As stated above, the disappointing outcome of synthetic vascular grafts and the limited
supply of autogafts necessitate tissue engineering approaches for constructing autologous
vessels. Vascular tissue engineering technology holds promise in the design of responsive
living conduits with properties similar to those of the native tissue40. In tissue engineering
of blood vessels, synthetic biodegradable, non-degradable or ECM scaffolds are
infiltrated with vascular cells and cultured under physiological conditions to mature
before implantation into the patient41-43 (Figure 2.4).
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Figure 2. 4: Schematic processes in tissue engineering showing the essential stages in
tissue fabrication
Tissue-engineered blood vessels thus have specific advantages since they are designed to
be responsive both mechanically and biologically with respect to the load that changes
with the hemodynamic environment. The first clinical application of a tissue-engineered
vascular construct was reported in 2001 for a paediatric patient with congenital single
ventricle cardiac anomaly.41 This was an exceptional case because no synthetic graft
could be used with the capacity to grow, repair, and remodel as required with normal
development. Since then, tissue-engineered conduits have been used for a total of 25
extracardiac cavopulmonary connections (median patient age 5.5 years) with only two
late cardiac failure deaths reported.44-47 The success of this procedure can be partially
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attributed to the relatively low-pressure environment (20 to 30 mmHg during systole)
found in pulmonary circulation, which is less demanding than pressures found in
coronary arteries (100 to 140 mmHg during systole). Despite the urgent need for an
engineered vascular tissue substitute, success is still limited.48 While engineering
approaches for other tissue substitutes can rely on in vivo remodelling to approach
functionality with time, tissue-engineered blood vessels must function immediately on
implantation − a significant challenge that contributed to its limited success.49 The long
lead time associated with the fabrication of an autologous vascular substitute is
commonly invoked as a major limitation to widespread clinical use. While this point may
be valid for emergency coronary artery surgical procedures or critically ischemic limbs,
in practice, most coronary and distal vascular bypass procedures can be predicted and
delayed over extended periods, allowing sufficient time for tissue fabrication.48
Clinical trials of engineered vascular substitutes for the adult population has been initiated
to examine the use of these grafts as arteriovenous shunts, as well as coronary and lower
limb bypass grafts.48 The initial clinical trial was focused on the safety of the
arteriovenous shunt model due to the lack of suitable vein for hemodialysis and the
deplorable efficacy of synthetic vascular grafts. Although graft failure in this model is
unlikely to be life or limb-threatening, the high flow rates encountered (ca. 800 ml/min)
generate considerable hemodynamic loads.48 Notwithstanding both technological and
regulatory challenges that lie ahead, engineered vascular tissues continued to be the "holy
grail" of future vascular intervention.50
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2.5 Engineered Vascular Tissues as Species-specific Predictive Organ Model
The use of vascular cells and whole sections of a harvested artery in combination with
animal models to study vascular diseases (e.g. atherosclerosis, post angioplasty restenosis,
and hypertension) in an attempt to develop therapeutics is not new but employing
engineered human vascular tissues for this role is a novel concept.51 While conventional
2D cell cultures are indispensable to our understanding of tissue morphogenesis and
function in physiological and pathological states, they do not accurately replicate the 3D
microenvironment of human tissues.52 For example, 2D culturing of vascular cells for
studying intimal hyperplasia without the arterial wall structure and extracellular matrix
(ECM) cannot recapitulate the intricate vascular wall mechanics and morphogenesis.53
Similarly, animal organ cultures and whole animal models do not completely mimic the
human biology due to the inevitable inter-species difference.54 Studies using closely
related nonhuman primates are constrained by limited availability, legal restrictions,
ethical concerns, and high cost making these animal models impractical.55

When

studying human vascular diseases and therapeutics, a realistic model is a human tissue but
the inability to experiment directly on human subjects limits this progress. Thus the need
for an engineered human vascular tissue model to close this gap is of vital importance.
Engineered human vascular tissues are not likely to replace animal or human subjects;
however, they have the potential to provide high throughput, substantive, and detailed
information regarding very specific conditions under controlled environments to study
disease models and therapeutic outcomes that are not possible with animal-based model.
The impact of successfully engineered human tissues is, therefore, not only restricted to
the clinic but also fills a critical gap in the pre-clinical model tool chest between
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traditional cell culture and whole animal experiments and has the potential to accelerate
the pace of basic biomedical research.56 A number of important physiological
characteristics of native tissues appear to be preserved in an engineered tissue; thus
providing models for specific disease conditions such as elevated contractility of vascular
smooth muscle cells in hypertension, elevated proliferation in atherosclerosis and postangioplasty restenosis and, fibrosis and cardiovascular remodeling.57-61 In this context,
engineered vascular tissue technology may be used both to validate drug targets and to
optimize loads. This allows for cardiovascular drug screening in a more controlled and
efficient way than can be performed using a traditional whole animal approach, thereby
minimizing the number of laboratory animals used and decreasing the overall cost of
performing research.56 In recent years, engineered 3D tissue models such as cardiac
patch62, lung tissue63, cornea64 and solid tumor65, 66 have emerged as powerful tools for
drug discovery. Although clinical applications of engineered 3D tissues attracted most
media attention, it is evident that engineered tissue models can serve as platforms for
tightly controlled, high-content screening of drugs and for pharmacodynamic analyses.

2.6 Engineered Vascular Tissues in Physiological Genomics Studies
Physiological genomics is an emerging field that brings together the disciplines of
genomics and cell, organ and whole animal systems integrative physiology in an effort to
to link gene products and pathways to phenotypes and physiological systems.56,

67

Physiological genomics study has traditionally been costly, requiring significant time to
breed and age animals before initiating expensive and time-consuming phenotyping
protocols.56 Towards this end, the use of in vitro fabricated 3D tissue systems to reduce
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the cost and time required for physiological genomic research is a relatively unexplored
concept (Figure 2.5).

Figure 2.5: Engineered tissue provides an opportunity for obtaining a wide variety
of phenotypes previously restricted to whole animal studies, including mechanical
measurements such as force of contraction, in an environment that more closely
replicates complex native tissue than 2D cell culture. This approach also captures
practical advantages of 2D culture, including the ability to make high-throughput
measurements and efficiently manipulate genomes. This unique model has the
potential to provide a link between whole animal and traditional culture approaches
to studying physiological genomics.56
Recent progress in miniaturizing engineered tissues and associated physiological assay
systems will accelerate our knowledge about interaction of the genome with both the
phenome and the environment.56 For example, using DNA microarrays with 9600 genes,
Chien and coworkers68 demonstrated that 77 vascular smooth muscle cells (VSMCs)
genes were expressed more than twofold and 22 genes were expressed less than one-half
in 3D matrix when compared with the 2D culture condition. Specifically, cells in 3D had
less stress fibers and focal adhesions, and a lower level of tyrosine phosphorylation of
focal adhesion kinase. The cyclin-dependent kinase inhibitor 1 (p21) was differentially
upregulated in 3D leading to lower VSMC proliferation. Collagen I expression was also
higher in 3D suggesting that VSMCs cultured on 3D matrix have increased ECM
synthesis. In addition, Mequanint and coworkers69 showed upregulation of the elastin
gene and downregulation of VSMC differentiation marker genes when cultured on 3D
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scaffolds compared with 2D surfaces. Differential gene expression is not limited to
vascular cells. Several groups have reported preliminary evidence that gene expression of
different cells cultured in 3D parallels more closely the in vivo situation.70 Gene
expression profiling experiments in various cell types clearly demonstrated close
correlation between engineered and native tissues in tumor cells71, tendon72, bone73, and
skin74. Collectively, these studies point to engineered tissue as a model system that could
be used to test gene expression and study the effect of altered gene expression on function
in vitro. In summary, successful application of these strategies may, in the near future,
allow investigators to identify the gene or genes responsible for a phenotype or disease
state in 3D culture rather than depending on the traditional positional cloning approach,
which often requires years of painstaking breeding and phenotypic studies.56

2.7 Essential Elements of Tissue Engineering
For tissue engineering to become a broadly accepted alternative for the treatment of
diseased or otherwise compromised tissues and organs there are a number of critical
elements that must still be addressed (Figure 2.6). These elements cover cell biology,
materials design, bioprocess engineering, and clinical outcome. In the following sections
each of the elements will be briefly discussed.
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Figure 2.6: Essential elements in tissue engineering.75 The fabrication of tissueengineered products that meet the needs of clinical efficacy, quality, and regulatory
requirements, manufacturing facility, and viable distribution mechanism requires
expertise in each of several basic areas of research and development. These include
cell sourcing and expansion, designing of biocompatible scaffolds that meet in vitro
and in vivo tissue growth demands, designing bioreactors and large-scale
manufacturing and preservation systems to enable cost-effective production and
distribution. Finally, strategies for solving immunological issues must be developed.
2.7.1 Cell Sourcing
In order to engineer a tissue, cells are undoubtedly the starting point that needs to be
considered. For vascular tissue engineering, the two main cell types needed are VSMCs
and endothelial cells (ECs). VSMCs constitute the main cellular components of the
tunica media of arterial vessels. In a mature artery, they display a contractile phenotype
with a very low proliferative activity and produce only small amounts of ECM proteins 76
while expressing contractile cytoskeletal marker proteins such as smooth muscle α-actin
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(SM-α-actin), smooth muscle myosin heavy chain (SMMHC), smoothelin-B, hcaldesmon and calponin; and contract in response to electrical, chemical and mechanical
stimuli.77,

78

However, VSMCs may also acquire a synthetic phenotype and become

predominantly proliferative if stimulated under certain biochemical and biomechanical
conditions. In the synthetic phenotype, VSMCs suppress the expression of genes that
define the contractile phenotype while rapidly upregulating genes required for
proliferation including matrix metalloproteinases and l-caldesmon.4,

79-82

During

vasculogenesis, VSMCs exist largely in the synthetic phenotype and synthesize ECM
proteins such as elastin, collagens and glycosaminoglycans.83 This phenotype modulation
is useful to engineer vascular substitutes. VSMCs can be sourced from either the patient
or a donor but the use of autologous cells is preferable since xenogenic and allogeneic
cells introduce potential risks for immunorejection.84, 85 One limitation of patient-specific
differentiated VSMCs is, however, their limited proliferative ability that results in
extended time for cell expansion.86-88 In order to overcome senescence, ectopic
expression of telomerase via human telomerase reverse transcriptase (hTERT) gene
transfection of adult VSMC has been studied.89,

90

Despite robust cell growth that

populated the scaffolds and resulted in a thick wall of the engineered artery, several issues
related to the safety of telomerised cells need to be resolved before these cells are
recommended for tissue engineering. For example, transfection with hTERT might lead
to uncontrolled growth leading to intimal hyperplasia and possibly tumor development.91
Recent advances in sourcing VSMCs for fabricating vascular tissues have shifted towards
stem cell niche with considerable success.92-96 Although VSMCs are the most studied in
the context of engineered tissue fabrication, ECs play a significant role for the overall
function of the engineered tissue. As such, a quiescent EC monolayer that regulates
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contractile VSMCs phenotype is an important requirement for functional tissueengineered vascular substitutes.97 ECs have a dynamic nature and interact with the
underlying VSMCs through direct cell-cell contact or through the synthesis and release of
mediators into the surrounding medium.98 In this thesis, human primary coronary artery
smooth muscle cells are used.

2.7.2 Scaffolds
With the exception of some studies 99-101, porous scaffolds which mimic the extracellular
matrix, are required for the 3D growth of cells to form engineered constructs.46,

102

Depending on the intended application, scaffolds may be designed to be biodegradable so
that only the native tissue will remain after a given period of culture time or it may be
biostable such that a composite tissue that provide long-term support could be
fabricated.42,

46, 103-105

In the case of biodegradable scaffolds, cells will remodel the

scaffold with their own ECM proteins creating the intended tissue without compromising
tissue structural integrity. This, however, requires strict coordination of the scaffold
biodegradation rate with the biosynthetic rate and is one of the major obstacles in the field
today. In addition, a scaffold must have several required characteristics: biocompatibility,
appropriate mechanical strength and compliance, optimal porosity for cell seeding, in
vitro nutrient and oxygen transport, and the ability to bind to cells and release growth
factors when needed.

Although some of these criteria could be met with existing

scaffolds, they do not provide biological cues for the cells imbedded in them and do not
interact with the cells. In the body, cells reside within the ECM, which provides tissues
with the appropriate architecture as well as signaling pathways that influence key cell
function such as migration, proliferation, and differentiation. Regeneration of tissues in
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vitro thus requires that cells be given a more specific level of instruction so that tissue
regeneration is successful. With the discovery of cell adhesion peptide domains in
fibronectin, collagen and laminin, the design of synthetic extracellular matrices with
biological activity has become an area of intense research activity.106-108 Scaffolds affect
cellular functions such as adhesion, migration, proliferation, differentiation and secretion
of ECM components.69

2.7.3 Bioreactors
A bioreactor is a dynamic in vitro environment that uses both biochemical and
mechanical signals to guide and regulate tissue developments.109 The concept of
bioreactors is neither new nor restricted to tissue engineering since cultivating proteins
from microbial or mammalian cells for therapeutic or diagnostic applications is wellknown.110, 111 They have been developed in response to static culture limitations and are
used to distribute cells uniformly on 3D scaffolds, provide the desired concentrations of
gases and nutrients in the culture medium, maintain efficient mass transfer to the growing
tissue, and apply a physical stimuli to the developing tissue.112,

113

Several bioreactor

designs such as rotating-wall, spinner flasks, and perfusion have been developed to
engineer a variety of tissues (Figure 2.7). In order to properly simulate physiological
conditions, vascular tissue engineering requires a system that mimics the hemodynamic
forces experienced by vascular tissues. These mechanical forces include shear stress and
stresses in the radial, circumferential and longitudinal directions. Shear stresses are
tangential frictional forces that are directly perceived by endothelial cells and indirectly
transmitted to smooth muscle cells as a result of interstitial flow and signalling.114-118
Initial attempts to create engineered blood vessels resulted in the manufacturing of grafts
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with poor mechanical properties.119 The next generation of tissue engineered vascular
substitutes had dramatically improved mechanical properties; however, it took several
months to develop tissue engineered vascular grafts with desired optimal mechanical
properties.100 Because elastin and collagen are the main two components of ECM that
determine the biomechanical properties of vascular tissues, dynamic mechanical
conditioning of the construct accelerates the production of these two proteins. For
example, the periodical radial distention resulted in accelerated maturation of engineered
vascular tissues.120, 121 In an in vitro experiment with a rabbit pulmonary artery subjected
to longitudinal stretch, the rate of elastin and collagen synthesis was related to the
magnitude of the longitudinal stretch.122 It has been also reported that endothelial cell and
smooth muscle cell proliferation rates in rabbit carotid arteries increased 50-fold and 15fold respectively after three days of longitudinal stretch in vivo.123 These data indicate
that longitudinal stretch of arteries is an important mechanical force for accelerated cell
proliferation, production of the ECM, and vascular remodeling.
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Figure 2.7: Summary of different bioreactors used for tissue fabrication.
The importance of mechanical forces on developing engineered vascular tissues is not
fully understood. Most cells persist in the state of dynamic flux where gases and
diffusible molecules may interact, either directly or indirectly as ligands by binding
specific receptors on the cell surface, and thus modulating cellular phenotype.124-126 Shear
forces act in a variety of different ways by acting on the endothelial cell membrane, thus
indirectly affecting the cell, by acting on the cell as a whole, or by stressing specific
molecules integrated into the cell membrane and transmit directly via transmembrane
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proteins connecting to the cells interior organelles or indirectly through cell signalling
cascades which lead to change in gene expression.21, 127, 128
Blood vessels are permanently subjected to mechanical forces in the form of stretch,
encompassing cyclic mechanical strain due to the pulsatile nature of blood flow and shear
stress. Blood pressure is the major determinant of vessel stretching. It creates radial and
tangential forces which counteract the effects of intraluminal pressure, and which affect
all cell types in the vessel. In comparison, fluid shear stress results from the friction of
blood against the vessel wall, and it acts in parallel to the vessel surface. Accordingly,
shear is sensed principally by endothelial cells located at the interface between the blood
and the vessel wall.129 Alterations in stretch or shear stress invariably produce
transformations in the vessel wall that will aim to accommodate the new conditions and to
ultimately restore basal levels of tensile stress and shear stress Hence, while acute
changes in stretch or shear stress correlate with transient adjustments in vessel diameter,
mediated through the release of vasoactive agonists or change in myogenic tone,
chronically altered mechanical forces usually instigate important adaptive alterations of
vessel wall shape and composition. The concept of vascular remodelling has therefore
been used to describe these transformations that occur in vessels undergoing mechanical
stresses.126, 130

2.8 Oxygen Mass Transfer in Tissues
2.8.1 The Challenges of Oxygen Transfer in Engineered Tissues
As discussed above, bioreactors have been developed with the intent to mechanically
stimulate the growing tissue constructs with physiologically relevant forces and to
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improve mass transfer within the tissue. Although the former is largely successful, the
later has shown to be a formidable engineering task. Therefore the delivery of nutrient
and the removal of metabolic waste materials remained to be a fundamental consideration
for fabricating engineered tissues. Oxygen delivery, in particular, is a limiting step for
clinically-relevant size tissues because of it is low solubility in culture media. This is
further exacerbated by the fact that cells consume five to six moles of oxygen per mole of
monosaccharide 131-133 according to the following mole balance.
C6H12O6 + 6O2→6CO2 + 6H2O
Clearly, the delivery of this much oxygen to cells required the development of oxygen
delivery system that is more efficient than molecular diffusion alone.
2.8.2 In Vivo Oxygen Transfer
In vivo, the above-mentioned limitation is mitigated by two specialized systems. First, the
presence of the circulatory system carries the oxygen in blood by convection (Table 2.1)
to the capillaries that are closer to the cells facilitating oxygen diffusion over shorter
distances.
Table 2. 1: Peak convection rates of blood in the vasculature.134
Compartment

cm/sec

Aorta

140±40

Common carotid

100±20

Vertebral

36±9

Femoral

90±13
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However, at an arterial pO2 (100 mmHg), only 0.3 ml oxygen dissolves in 100 ml plasma.
Given that a human body needs 250 ml oxygen per minute,134 plasma-dissolved oxygen
contributes only to 15 ml/min at a cardiac output of 5 L/min. In the absence of an oxygen
carrier, this translates to a cardiac output of 83 L/min which is impossible. This limitation
is addressed by a second specialized system in which the oxygen carrier protein,
hemoglobin, overcomes the very low solubility of oxygen in plasma.

2.8.3 The Oxygen-hemoglobin Dissociation Curve
The cooperative binding of oxygen to hemoglobin is described by the oxygenhemoglobin dissociation curve. This is an equilibrium curve that expresses the fractional
occupancy of the hemoglobin oxygen binding sites (Y) at a given oxygen partial pressure
(pO2) (Figure 2.7).
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Figure 2.8: Changes in the oxygen-hemoglobin dissociation curve.135 A shift to the
right is often caused by increased CO2 concentration or a decreased pH. The
opposite is true for the shift to the left.
The equilibrium oxygen partial pressure above the solution of blood is related to the
dissolved oxygen concentration by Henry’s law.
yP ≡ pO2 =
ΗC

(1)

 mmHg 
In the above equation, H is the Henry constant, which is 0.74 
 for oxygen, C is
 μM 
the dissolved oxygen concentration (µM) and y is the mole fraction of oxygen in the gas
phase. It will be important to realize that the pO2 is exerted only by the dissolved oxygen.
The oxygen bound to the hemoglobin does not affect pO2 but serves only as a source for
oxygen. With this in mind, hemoglobin bound oxygen is transported by the circulatory
system to the capillaries where a change in the pO2 levels along the length of the capillary
causes oxygen to be released. This released oxygen then diffuses across the capillary wall
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to reach the cells. The binding and releasing of oxygen to hemoglobin is represented by
Hill’s equation.
Hb(O 2 ) n ↔ Hb + nO 2

(2)

d [ Hb ]
n
= k1 [ Hb(O2 ) n ] − k−1 [ Hb ][O2 ]
dt

(3)

Where k1 and k-1 are the association and dissociation rate constants respectively.
The overall equation can also be written as:
=
[ Hb(O2 )n ] k=
[ Hb][O2 ] ; where k k−1 / k1
n

(4)

The oxygen demand of a tissue can be calculated through the basic material balances on a
controlled volume. Let Г represent the tissue metabolic volumetric oxygen consumption

 µM 
rate in 
, Vt is volume of the tissue space (including the capillaries), q is the tissue
 sec 
blood perfusion rate (mL of blood /cm3 tissue/min), C is dissolved oxygen in plasma
(μM), C' the concentration of oxygen in the blood that is bound to the hemoglobin (μM),
Ct represents the concentration of oxygen dissolved in the interstitial space of the tissue
(μM), Pc represents the permeability of oxygen through the capillary wall and Sc
represents the total surface area of the capillaries (cm3). The mass balance in the blood
will be:
0 = qV (C + C ') A − qV (C + C ')V − Pc Sc (Cv − Ct )

Whereas the mass balance in the tissue is:

(5)
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=
0 Pc Sc (Cv − Ct ) − Vt Γ

(6)

Combining equations (5) and (6) the metabolic oxygen consumption is given by,
=
Γ q [ (C + C ') A − (C + C ')V ]

(7)

At the normal tissue perfusion rate of 0.5 ml of blood /cm3 tissue/min, taking the partial
pressure of oxygen in arterial and venous blood to be around 100 and 40 mmHg
respectively, and assuming the density of the tissue ~1g/cm3, Г will be 23µ M / sec . The
experimentally measured average body oxygen consumption value reported in the
literatures is in the order of 20 µ M / sec which is in good agreement with the predicted
value. 136

2.8.4 Alternative Oxygen Binding Chemicals
The search for alternative oxygen binding chemicals has been and still remained to be an
active area of research.137 From a clinical standpoint, this has been fuelled by increasing
negative public perceptions about blood safety coupled with the potential risk of
transmitting diseases due to transfusion.138,

139

The use of a blood substitute during

surgery will reduce patient exposure to donor blood, thereby minimizing disease
transmission and preventing other unwanted transfusion-related complications especially
immunomodulatory reactions.139 Alternative oxygen binding chemicals broadly fall in
one of two categories: i) modified hemoglobin derived either from human and animal
sources and crosslinked to improve intravascular persistence times or engineered
genetically using recombinant technology.140,

141

ii) synthetic, inert, perfluorinated
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compounds (PFC).142 Due to the relevance of PFCs to the work in this thesis, pertinent
review is presented in the following section.

2.9 The Chemistry of Perfluorocarbon Compounds
PFCs are organic compounds whose hydrogen atoms in the carbon network are replaced
by fluorine atoms. There is no surprise that replacing all the hydrogen atoms by fluorine
in an organic molecule should bring significant changes in the properties of the resulting
compound. Since all electrons in fluorine atom are packed in a proportionally less space,
fluorine has a much denser electron cloud and higher ionization potential compared with
hydrogen. The thermodynamic stability of PFCs is derived from the enhanced match
between the carbon and fluorine orbitals as compared to that between carbon and
hydrogen - leading to the strongest single bond (ca. 530 kJ/mol) found in PFC
compounds.143 Furthermore, the extreme electron attracting character of fluorine
enhances the C-C bond energy in the skeleton by "shrinking"’ the orbitals of the carbons.
These factors are responsible for the inertness of PFCs since there exists no low energy
molecular orbitals accessible for reaction as the fluorine atoms shield the C-C skeleton
sterically.143 Given that PFCs are extremely stable and inert to many aggressive
environments, they are also not metabolized as there are no enzymes able to break them
down.

2.9.1 Oxygen Solubility in PFCs
PFCs have unique characteristics of low water and lipid solubility (i.e hydrophobic and
lipophobic) but high dissolving power for oxygen and carbon dioxide making them
attractive for both chemical and biological research.144 Gas solubility is a result of
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fluorine's low polarizability which translates to low van der Waals intermolecular
interaction within the PFC molecule. Since van der Waals interactions are the only
intermolecular forces that hold non-polar compounds together, these forces are feeble, in
contrast with their intramolecular bonds. This low cohesive energy density in PFC
compounds dissolves another low cohesive energy density compound such as oxygen
(Figure 2.9).

Figure 2.9: Oxygen solubility in different hydrocarbons and fluorocarbons.143
Oxygen binds to hemoglobin by strong, localized chemical coordinate bond established
between the oxygen molecule and the iron atom of a heme. In the case of PFC, however,
there is a physical dissolution of oxygen characterized by loose non-directional van der
Waals interaction among like materials144. The difference in these interactions reflects the
difference in oxygen uptake curves as a function of pO2 which is sigmoid for hemoglobin
and linear for PFC. The linearity is the result of Henry's law in which solubility is directly
proportional to the gas’s partial pressure, and not a localized chemical binding situation as
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in hemoglobin. Consequent to this, oxygen can be rapidly and extensively extracted from
PFCs when needed.

2.9.2 PFCs as Oxygen Delivery Systems
Their high oxygen dissolving power and outstanding chemical and biological inertness is
the basis that made PFCs as candidates for in vivo O2 delivery.143 Although the ability of
PFC in dissolving larger amounts of gases than any other solvent was already known,
Clark and Gollan145 were the first to demonstrate that mice could live while breathing an
O2-saturated liquid PFC without any harm to the animals. As indicated earlier, PFCs are
both hydrophobic and lipophobic and thus are insoluble in water and lipids - two of the
most abundant biological fluids. The PFC-water interfacial tension which opposes the
dispersion of PFCs in water can reach as high as 60 mN/m. In order to effectively use
them, they must be emulsified  demanding a stable, injectable, small-sized, narrowly
distributed PFC emulsion (Figure 2.10). The non-ideal nature of the PFC-water solution
suggests the difficulty to store the emulsion for an extended period of time.

Figure 2.10: Preparation of perfluorocarbon emulsion using surfactants and
dispersion energy in order to overcome the PFC-water interfacial tension. Terminal
heat sterilization is achieved in a rotary sterilizer.143
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The first preparation of a physiologically adjusted PFC emulsion was reported by Sloviter
and Kamimoto using bovine serum albumin as a surfactant.146 Following this early report,
a triblock copolymer of poly(ethylene oxide) and poly (propylene oxide), egg yolk
phospholipids, potassium oleate and fluorinated surfactants or any combination thereof
have been investigated as emulsifiers.137 Although pure PFCs are not toxic at all, the
toxicity of PFC emulsions to cultured cells is attributed to the emulsifiers used. Within
the context of tissue engineering, PFCs have been shown to enhance oxygen delivery to
the growing tissue construct, despite some limitation such as droplet settling due to
density differences.147, 148

2.10 Diffusion in Porous Media and Its Relevance in Tissue Engineering
It was stated earlier that one of the essential elements in tissue engineering is a porous 3D
scaffold with interconnected pores. A porous 3D scaffold mimics the pores present within
the extracellular fibrous matrix.136 One important parameter in the study of porous
materials is tortuosity149 which is the ratio of the minimum inter-pore distance between
two pores to the shortest distance between those pores. The movement of fluid molecule
in a porous media follows tortuous pathways in the scaffold void space. Fluid flow
governing equations in porous media can be numerically solved for the individual pores if
the structures of the pore networks are known. Alternatively, the porous medium could be
assumed to be a uniform material in a continuum approach and solved by using Darcy's
law. In this later approach, there are three length scales namely: the average size (δ) of
the pore, the distance (L) over which macroscopic change of physical quantities (e.g. fluid
velocity and pressure) must be considered, and another length ( l ) between L and δ. This
last length scale is introduced since L is chosen be the characteristic linear dimension of
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the porous medium (e.g. the size of the scaffold, or the size of the tissue) and is required
to be at least two orders of magnitude larger than δ.135 To define l , a volume of
dimension l in the porous medium is considered. The volume fraction of the void space
is then the volumetric porosity (ε) and, the volume fraction of the solid phase is equal to
1- ε. When l is closer to δ, ε is more sensitive to the value of l . Conversely, when l is
selected to be large, the sensitivity decreases. There exists a value of l beyond which the
sensitivity is minimal. In biological tissue δ < 0.1µm , l ≈ 1µ m and L ≈ 100µm allowing
transport in biological tissues or scaffolds to be studied with the continuum approach.135
Fluid transport in scaffolds must also satisfy the conservation of mass. Because both fluid
production and fluid consumption are present when cells are seeded to scaffolds and
cultured, the mass balance

∇v = φ B − φ L

(8)

∇ε v f =ϕ B − ϕ L

(9)

Where, v is the fluid average velocity in representative volume, v f is fluid average
velocity in the volume, φB and φL are volumetric flow rates per unit volume of porous
medium in sources and sinks respectively. The values of φB and φL are determined by
Starling’s Law.

∇v = φ B − φ L

(10)

Where Jv is flow rate, S is the surface area, Lp is the hydraulic conductivity, P is the
hydrostatic pressure and π is the osmotic pressure.

34
It is also possible to express the velocity as follows:

v =− K ∇P

(11)

∇P is the gradient of hydrostatic pressure and K is hydrostatic conductivity. In
combination with equation (8)

∇(− K ∇P)= φB − φL

(12)

Equations (11) and (12) are the governing equations for fluid flow in porous media. The
scaffolds interstitial space can be considered a network of channels filled with porous
media. Fluid flow in such channels may be correctly modeled by Darcy’s law. When the
specific permeability (k) of the porous media is low, equation (12) become the Brinkman
equation.

µ∇V −

µ
K

V − ∇P = 0

(13)

These equations were used to model flow behavior in scaffolds and vascular tissue
engineering bioreactors.150-152

2.10.1 Squeeze Flow in Porous Scaffolds
Squeeze flow refers to the fluid flow caused by the relative movement of solid boundaries
towards each other. The boundaries can be either external or internal for fluid flow in a
porous scaffold. Squeeze flow is applicable in the interstitial space of vascular tissue
engineering scaffolds; because it mimics the compliance of the vasculature in response to
the pulsatile force generated by the heart.153-155
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Figure 2.11: Squeeze flow model. The two boundaries are moving to each other at a
velocity of Vh, and the space between them is 2h.

Squeeze flow is best expressed by equation (13). In a cylindrical coordinate there is no
pressure gradient in z direction and hence

µ

∂P
= 0 . With this we have:
∂z

∂ 2Vr µ
∂P
0
− Vr −
=
2
∂z
k
∂r

(14)

Where k is the specific permeability of the scaffold. The equation is subject to the
following boundary conditions:

Vr = 0 z =h , and

∂Vr
=0
∂r
z =0

The solution for (14) is then
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In a cylindrical coordinate system, the continuity equation is written as:

1 ∂ (rVr ) ∂Vz
0
+
=
r ∂r
∂z

(18)

Subject to the boundary conditions Vz = Vh z =h , and Vz = 0 z =0 , the solution leads to:

 ∂ 2 P 1 ∂P 
=  2 +

r ∂r 
k k
 h  h   ∂r
tanh 

−
µ 
k
 k
Vh

(19)

Thus solving (19) for the second order differential equation will give the pressure
distribution as:

r2
P = A + B ln r + C
4

(20)

Using the boundary conditions,
∂P
= 0 , and P = Po r = R
∂r
r =0

Vh
P=
Po +
(r 2 − R 2 )
4k k 
 h  h 
tanh 


−
µ 
k
 k

(21)

Therefore, equations (19-21) provide the fluid velocity and pressure profiles for a squeeze
flow. The velocity profile will provide the sheer stress distribution in the scaffold which
is one of the parameters to be considered in dynamic cell culture experiments. The utility

37
of squeeze flow model has been demonstrated in cartilage, bone, and vascular tissue
engineering strategies.156-160

2.10.2 Lattice Boltzmann’s Approach for Porous Fluid Flow
The Lattice–Boltzmann method with computational fluid dynamics has been used to
simulate the flow conditions within perfused cell-seeded cylindrical scaffolds.161,

162

Microcomputed tomography imaging is used to define the scaffold micro-architecture for
the simulations, which produces a 3D fluid velocity field throughout the scaffold porosity.
Shear stresses are then estimated at various media flow rates by multiplying the
symmetric part of the gradient of the velocity field by the dynamic viscosity of the cell
culture media. The shear stress algorithm was validated by modeling flow between
infinite parallel plates and comparing the calculated shear stress distribution to the
analytical solution. The simulation results relating to perfusion experiments gave an
average surface shear stress to correspond to increased cell proliferation, while higher
shear stresses were associated with upregulation of bone marker genes. Even though this
model has been used for cartilage and bone tissue engineering, it is primarily used to
compare results obtained for different perfusion bioreactor systems or different scaffold
micro-architectures and may allow specific shear stresses to be determined that optimize
the amount, type, or distribution of in vitro tissue growth transport. In particular, it is
applicable and equally usable in vascular tissue engineering with load applied
bioreactors.163-165
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2.11 Summary
In the preceding sections, literature review pertinent to this thesis is presented. Due to
rapid advances made in tissue engineering, it was not possible to include all aspects of the
field. However, every effort is made to ensure that seminal works and significant research
findings are included, with minimal bias, in this Chapter. Notwithstanding the different
challenges and opportunities presented by tissue engineering strategies, this thesis will
only attempt to address oxygen mass transfer limitations in engineered tissue constructs.

2.12 Hypothesis and Objectives of the Study
It is hypothesized that 3D polyurethane scaffolds with interconnected pores enhance
oxygen diffusivity. It is further hypothesized that oxygen delivery strategies using PFC
enhances mass transfer and human coronary artery smooth muscle cells (HCASMC)
infiltration when seeded into 3D polyurethane. In order to test the above hypotheses, the
following objectives were formulated:
•

Fabricating 3D porous poly (carbonate urethane) (PCU) scaffolds using a pressure
differential/particulate leaching technique at different PCU concentration.

•

Measuring of effective diffusivity of oxygen through PCU 3D scaffolds

•

Developing a mathematical model for oxygen profile on cell seeded 3D scaffold
and in the lumen channel.

•

Evaluating the supply of oxygen to HCASMC seeded on 3D PCU scaffolds using
oxygen carrier particles embedded in the scaffold.

39
2.13 References
1.

Bohl, K. S.; West, J. L., Nitric oxide-generating polymers reduce platelet adhesion
and smooth muscle cell proliferation. Biomaterials 2000, 21, (22), 2273-8.

2.

Ross, R., The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature
1993, 362, (6423), 801-9.

3.

D'Armiento, J., Decreased elastin in vessel walls puts the pressure on. J Clin
Invest 2003, 112, (9), 1308-10.

4.

Owens, G. K.; Kumar, M. S.; Wamhoff, B. R., Molecular regulation of vascular
smooth muscle cell differentiation in development and disease. Physiol Rev 2004,
84, (3), 767-801.

5.

Martini, F. H., Fundamentals of Anatomy and physiology. Prentice Hall: 1998; p
710 and 712.

6.

Fawcett, D. W., Bloom and Fawcett: A Textbook of Histology. 12 ed.; A Hodder
Arnold Publication: 1997; p 368-409.

7.

Lusis, A. J., Atherosclerosis. Nature 2000, 407, (6801), 233-41.

8.

Yamanaka, O.; Hobbs, R. E., Coronary artery anomalies in 126,595 patients
undergoing coronary arteriography. Cathet Cardiovasc Diagn 1990, 21, (1), 2840.

9.

Engel, H. J.; Torres, C.; Page, H. L., Jr., Major variations in anatomical origin of
the coronary arteries: angiographic observations in 4,250 patients without
associated congenital heart disease. Cathet Cardiovasc Diagn 1975, 1, (2), 15769.

10.

Fernandes, E. D.; Kadivar, H.; Hallman, G. L.; Reul, G. J.; Ott, D. A.; Cooley, D.
A., Congenital malformations of the coronary arteries: the Texas Heart Institute
experience. Ann Thorac Surg 1992, 54, (4), 732-40.

11.

Byrum, C. J.; Blackman, M. S.; Schneider, B.; Sondheimer, H. M.; Kavey, R. E.,
Congenital atresia of the left coronary ostium and hypoplasia of the left main
coronary artery. Am Heart J 1980, 99, (3), 354-8.

12.

Musiani, A.; Cernigliaro, C.; Sansa, M.; Maselli, D.; De Gasperis, C., Left main
coronary artery atresia: literature review and therapeutical considerations. Eur J
Cardiothorac Surg 1997, 11, (3), 505-14.

13.

Desmet, W.; Vanhaecke, J.; Vrolix, M.; Van de Werf, F.; Piessens, J.; Willems, J.;
de Geest, H., Isolated single coronary artery: a review of 50,000 consecutive
coronary angiographies. Eur Heart J 1992, 13, (12), 1637-40.

40
14.

Grabow, N.; Martin, D. P.; Schmitz, K. P.; Sternberg, K., Absorbable polymer
stent technologies for vascular regeneration. J Chem Technol Biotechnol 2010, 85,
(6), 744-751.

15.

Sabik, J. F., 3rd, Understanding saphenous vein graft patency. Circulation 2011,
124, (3), 273-5.

16.

Verma, S.; Szmitko, P. E.; Weisel, R. D.; Bonneau, D.; Latter, D.; Errett, L.;
LeClerc, Y.; Fremes, S. E., Should radial arteries be used routinely for coronary
artery bypass grafting? Circulation 2004, 110, (5), e40-6.

17.

Desai, N. D.; Cohen, E. A.; Naylor, C. D.; Fremes, S. E., A randomized
comparison of radial-artery and saphenous-vein coronary bypass grafts. N Eng J
Med 2004, 351, (22), 2302-2309.

18.

Kobayashi, J., Current status of coronary artery bypass grafting. Gen Thorac
Cardiovasc Surg 2008, 56, (6), 260-267.

19.

Schmitto, J. D.; Rajab, T. K.; Cohn, L. H., Prevalence and variability of internal
mammary graft use in contemporary multivessel coronary artery bypass graft.
Curr Opin Cardiol 2010, 25, (6), 609-612.

20.

Owens, C. D.; Wake, N.; Conte, M. S.; Gerhard-Herman, M.; Beckman, J. A., In
vivo human lower extremity saphenous vein bypass grafts manifest flow mediated
vasodilation. J Vasc Surg 2009, 50, (5), 1063-1070.

21.

Akowuah, E. F.; Sheridan, P. J.; Cooper, G. J.; Newman, C., Preventing
saphenous vein graft failure: Does gene therapy have a role? Ann Thorac Surg
2003, 76, (3), 959-966.

22.

Tatoulis, J.; Buxton, B. F.; Fuller, J. A.; Meswani, M.; Theodore, S.; Powar, N.;
Wynne, R., Long-Term Patency of 1108 Radial Arterial-Coronary Angiograms
Over 10 Years. Ann Thorac Surg 2009, 88, (1), 23-30.

23.

Weintraub, W. S.; Jones, E. L.; Craver, J. M.; Guyton, R. A., Frequency of Repeat
Coronary-Bypass or Coronary Angioplasty after Coronary-Artery Bypass-Surgery
Using Saphenous Venous Grafts. Am J Cardiol 1994, 73, (2), 103-112.

24.

Kannan, R. Y.; Salacinski, H. J.; Butler, P. E.; Hamilton, G.; Seifalian, A. M.,
Current status of prosthetic bypass grafts: A review. J Biomed Mater Res B 2005,
74B, (1), 570-581.

25.

Rashid, S. T.; Fuller, B.; Hamilton, G.; Seifalian, A. M., Tissue engineering of a
hybrid bypass graft for coronary and lower limb bypass surgery. FASEB J 2008,
22, (6), 2084-2089.

26.

Maisel, W. H., A device for proximal anastomosis of autologous coronary vein
grafts - Report from the meeting of the circulatory system devices panel of the

41
food and drug administration center for devices and radiologic health. Circulation
2005, 112, (10), 1516-1518.
27.

Abbott, W. M., Evaluation and Performance Standards for Arterial Prostheses Reply. J Vasc Surg 1995, 21, (3), 543-543.

28.

Bennion, R. S.; Williams, R. A.; Stabile, B. E.; Fox, M. A.; Owens, M. L.;
Wilson, S. E., Patency of Autogenous Saphenous-Vein Versus
Polytetrafluoroethylene Grafts in Femoropopliteal Bypass for Advanced Ischemia
of the Extremity. Surg Gynecol Obstet 1985, 160, (3), 239-242.

29.

Kannan, R. Y.; Salacinski, H. J.; Butler, P. E.; Hamilton, G.; Seifalian, A. M.,
Current status of prosthetic bypass grafts: a review. J Biomed Mater Res B 2005,
74, (1), 570-81.

30.

Hoenig, M. R.; Campbell, G. R.; Rolfe, B. E.; Campbell, J. H., Tissue-engineered
blood vessels: alternative to autologous grafts? Arterioscler Thromb Vasc Biol
2005, 25, (6), 1128-34.

31.

Baguneid, M.; de Mel, A.; Yildirimer, L.; Fuller, B. J.; Hamilton, G.; Seifalian, A.
M., In vivo study of a model tissue-engineered small-diameter vascular bypass
graft. Biotechnol App Bioc 2011, 58, (1), 14-24.

32.

Desai, M.; Seifalian, A. M.; Hamilton, G., Role of prosthetic conduits in coronary
artery bypass grafting. Eur J Cardio-Thorac 2011, 40, (2), 394-398.

33.

Zilla, P.; Bezuidenhout, D.; Human, P., Prosthetic vascular grafts: Wrong models,
wrong questions and no healing. Biomaterials 2007, 28, (34), 5009-5027.

34.

Annis, D., Polyether-Urethane Elastomers for Small-Diameter Arterial Prostheses.
Life Support Syst 1987, 5, (1), 47-52.

35.

Grasl, C.; Bergmeister, H.; Stoiber, M.; Schima, H.; Weigel, G., Electrospun
polyurethane vascular grafts: In vitro mechanical behavior and endothelial
adhesion molecule expression. J Biomed Mater Res A 2010, 93A, (2), 716-723.

36.

Tiwari, A.; Salacinski, H.; Seifalian, A. M.; Hamilton, G., New prostheses for use
in bypass grafts with special emphasis on polyurethanes. Cardiovasc Surg 2002,
10, (3), 191-7.

37.

Brothers, T. E.; Stanley, J. C.; Burkel, W. E.; Graham, L. M., Small-caliber
polyurethane and polytetrafluoroethylene grafts: a comparative study in a canine
aortoiliac model. J Biomed Mater Res 1990, 24, (6), 761-71.

38.

Rashid, S. T.; Salacinski, H. J.; Button, M. J. C.; Fuller, B.; Hamilton, G.;
Seifalian, A. M., Cellular engineering of conduits for coronary and lower limb
bypass surgery: Role of cell attachment peptides and pre-conditioning in
optimising smooth muscle cells (SMC) adherence to compliant poly(carbonate-

42
urea)urethane (MyoLink((TM))) scaffolds. Eur J Vasc Endovasc 2004, 27, (6),
608-616.
39.

Seifalian, A. M.; Salacinski, H. J.; Tiwari, A.; Edwards, A.; Bowald, S.; Hamilton,
G., In vivo biostability of a poly(carbonate-urea)urethane graft. Biomaterials
2003, 24, (14), 2549-2557.

40.

Stegemann, J. P.; Kaszuba, S. N.; Rowe, S. L., Review: advances in vascular
tissue engineering using protein-based biomaterials. Tissue Eng 2007, 13, (11),
2601-13.

41.

Shin'oka, T.; Imai, Y.; Ikada, Y., Transplantation of a tissue-engineered
pulmonary artery. N Engl J Med 2001, 344, (7), 532-3.

42.

Grenier, S.; Sandig, M.; Holdsworth, D. W.; Mequanint, K., Interactions of
coronary artery smooth muscle cells with 3D porous polyurethane scaffolds. J
Biomed Mater Res A 2009, 89, (2), 293-303.

43.

Grenier, S.; Sandig, M.; Mequanint, K., Smooth Muscle alpha-actin and Calponin
Expression and, Extracellular Matrix Production of Human Coronary Artery
Smooth Muscle Cells in 3D Scaffolds. Tissue Eng Part A 2009, 15, (10), 30013011.

44.

Shinoka, T.; Breuer, C., Tissue-engineered blood vessels in pediatric cardiac
surgery. Yale J Biol Med 2008, 81, (4), 161-6.

45.

Hibino, N.; McGillicuddy, E.; Matsumura, G.; Ichihara, Y.; Naito, Y.; Breuer, C.;
Shinoka, T., Late-term results of tissue-engineered vascular grafts in humans. J
Thorac Cardiovasc Surg 2010, 139, (2), 431-6, 436 e1-2.

46.

Naito, Y.; Shinoka, T.; Duncan, D.; Hibino, N.; Solomon, D.; Cleary, M.;
Rathore, A.; Fein, C.; Church, S.; Breuer, C., Vascular tissue engineering: towards
the next generation vascular grafts. Adv Drug Deliv Rev 2011, 63, (4-5), 312-23.

47.

Duncan, D. R.; Breuer, C. K., Challenges in translating vascular tissue
engineering to the pediatric clinic. Vasc Cell 2011, 3, (1), 23.

48.

L'Heureux, N.; Dusserre, N.; Marini, A.; Garrido, S.; de la Fuente, L.; McAllister,
T., Technology insight: the evolution of tissue-engineered vascular grafts--from
research to clinical practice. Nat Clin Pract Cardiovasc Med 2007, 4, (7), 389-95.

49.

Patel, A.; Fine, B.; Sandig, M.; Mequanint, K., Elastin biosynthesis: The missing
link in tissue-engineered blood vessels. Cardiovasc Res 2006, 71, (1), 40-9.

50.

Dolgin, E., Taking tissue engineering to heart. Nat Med 2011, 17, (9), 1032-5.

51.

Raimondi, M. T., Engineered tissue as a model to study cell and tissue function
from a biophysical perspective. Curr Drug Discov Technol 2006, 3, (4), 245-68.

43
52.

Goodbye, flat biology? Nature 2003, 424, (6951), 861.

53.

Swanson, N.; Javed, Q.; Hogrefe, K.; Gershlick, A., Human internal mammary
artery organ culture model of coronary stenting: a novel investigation of smooth
muscle cell response to drug-eluting stents. Clin Sci (Lond) 2002, 103, (4), 34753.

54.

Touchard, A. G.; Schwartz, R. S., Preclinical restenosis models: challenges and
successes. Toxicol Pathol 2006, 34, (1), 11-8.

55.

Macchiarini, F.; Manz, M. G.; Palucka, A. K.; Shultz, L. D., Humanized mice: are
we there yet? J Exp Med 2005, 202, (10), 1307-11.

56.

Petersen, M. C.; Lazar, J.; Jacob, H. J.; Wakatsuki, T., Tissue engineering: a new
frontier in physiological genomics. Physiol Genomics 2007, 32, (1), 28-32.

57.

Auger, F. A.; D'Orleans-Juste, P.; Germain, L., Adventitia contribution to vascular
contraction: hints provided by tissue-engineered substitutes. Cardiovasc Res 2007,
75, (4), 669-78.

58.

Laflamme, K.; Roberge, C. J.; Grenier, G.; Remy-Zolghadri, M.; Pouliot, S.;
Baker, K.; Labbe, R.; D'Orleans-Juste, P.; Auger, F. A.; Germain, L., Adventitia
contribution in vascular tone: insights from adventitia-derived cells in a tissueengineered human blood vessel. FASEB J 2006, 20, (8), 1245-7.

59.

Laflamme, K.; Roberge, C. J.; Pouliot, S.; D'Orleans-Juste, P.; Auger, F. A.;
Germain, L., Tissue-engineered human vascular media produced in vitro by the
self-assembly approach present functional properties similar to those of their
native blood vessels. Tissue Eng 2006, 12, (8), 2275-81.

60.

Elliott, N. T.; Yuan, F., A review of three-dimensional in vitro tissue models for
drug discovery and transport studies. J Pharm Sci 2011, 100, (1), 59-74.

61.

L'Heureux, N.; Stoclet, J. C.; Auger, F. A.; Lagaud, G. J.; Germain, L.;
Andriantsitohaina, R., A human tissue-engineered vascular media: a new model
for pharmacological studies of contractile responses. FASEB J 2001, 15, (2), 51524.

62.

Katare, R. G.; Ando, M.; Kakinuma, Y.; Sato, T., Engineered heart tissue: a novel
tool to study the ischemic changes of the heart in vitro. PLoS One 2010, 5, (2),
e9275.

63.

Huh, D.; Matthews, B. D.; Mammoto, A.; Montoya-Zavala, M.; Hsin, H. Y.;
Ingber, D. E., Reconstituting organ-level lung functions on a chip. Science 2010,
328, (5986), 1662-8.

44
64.

Reichl, S.; Dohring, S.; Bednarz, J.; Muller-Goymann, C. C., Human cornea
construct HCC-an alternative for in vitro permeation studies? A comparison with
human donor corneas. Eur J Pharm Biopharm 2005, 60, (2), 305-8.

65.

Verbridge, S. S.; Choi, N. W.; Zheng, Y.; Brooks, D. J.; Stroock, A. D.;
Fischbach, C., Oxygen-controlled three-dimensional cultures to analyze tumor
angiogenesis. Tissue Eng Part A 2010, 16, (7), 2133-41.

66.

Hutmacher, D. W.; Horch, R. E.; Loessner, D.; Rizzi, S.; Sieh, S.; Reichert, J. C.;
Clements, J. A.; Beier, J. P.; Arkudas, A.; Bleiziffer, O.; Kneser, U., Translating
tissue engineering technology platforms into cancer research. J Cell Mol Med
2009, 13, (8A), 1417-27.

67.

Cowley, A. W., Physiological genomics: tools and concepts. J Physiol 2004, 554,
(Pt 1), 3.

68.

Li, S.; Lao, J.; Chen, B. P.; Li, Y. S.; Zhao, Y.; Chu, J.; Chen, K. D.; Tsou, T. C.;
Peck, K.; Chien, S., Genomic analysis of smooth muscle cells in 3-dimensional
collagen matrix. FASEB J 2003, 17, (1), 97-9.

69.

Lin, S.; Sandig, M.; Mequanint, K., Three-dimensional topography of synthetic
scaffolds induces elastin synthesis by human coronary artery smooth muscle cells.
Tissue Eng Part A 2011, 17, (11-12), 1561-71.

70.

Birgersdotter, A.; Sandberg, R.; Ernberg, I., Gene expression perturbation in vitro-a growing case for three-dimensional (3D) culture systems. Semin Cancer Biol
2005, 15, (5), 405-12.

71.

Ghosh, S.; Spagnoli, G. C.; Martin, I.; Ploegert, S.; Demougin, P.; Heberer, M.;
Reschner, A., Three-dimensional culture of melanoma cells profoundly affects
gene expression profile: a high density oligonucleotide array study. J Cell Physiol
2005, 204, (2), 522-31.

72.

Sawaguchi, N.; Majima, T.; Iwasaki, N.; Funakoshi, T.; Shimode, K.; Onodera,
T.; Minami, A., Extracellular matrix modulates expression of cell-surface
proteoglycan genes in fibroblasts. Connect Tissue Res 2006, 47, (3), 141-8.

73.

Hamamura, K.; Jiang, C.; Yokota, H., ECM-dependent mRNA expression profiles
and phosphorylation patterns of p130Cas, FAK, ERK and p38 MAPK of
osteoblast-like cells. Cell Biol Int 2010, 34, (10), 1005-12.

74.

Smiley, A. K.; Klingenberg, J. M.; Aronow, B. J.; Boyce, S. T.; Kitzmiller, W. J.;
Supp, D. M., Microarray analysis of gene expression in cultured skin substitutes
compared with native human skin. J Invest Dermatol 2005, 125, (6), 1286-301.

75.

Naughton, G. K., From lab bench to market: critical issues in tissue engineering.
Ann N Y Acad Sci 2002, 961, 372-85.

45
76.

Wamhoff, B. R.; Bowles, D. K.; Owens, G. K., Excitation-transcription coupling
in arterial smooth muscle. Circ Res 2006, 98, (7), 868-78.

77.

Owens, G. K., Regulation of differentiation of vascular smooth muscle cells.
Physiol Rev 1995, 75, (3), 487-517.

78.

Rensen, S. S.; Thijssen, V. L.; De Vries, C. J.; Doevendans, P. A.; DeteraWadleigh, S. D.; Van Eys, G. J., Expression of the smoothelin gene is mediated
by alternative promoters. Cardiovasc Res 2002, 55, (4), 850-63.

79.

Ueki, N.; Sobue, K.; Kanda, K.; Hada, T.; Higashino, K., Expression of high and
low molecular weight caldesmons during phenotypic modulation of smooth
muscle cells. Proc Natl Acad Sci U S A 1987, 84, (24), 9049-53.

80.

Sobue, K.; Hayashi, K.; Nishida, W., Expressional regulation of smooth muscle
cell-specific genes in association with phenotypic modulation. Mol Cell Biochem
1999, 190, (1-2), 105-118.

81.

Menon, C.; Chacko, S., Expression of smooth muscle caldesmon in developing
chicken gizzard. Tissue Cell 1998, 30, (1), 118-26.

82.

Kumar, M. S.; Owens, G. K., Combinatorial control of smooth muscle-specific
gene expression. Arterioscl Throm Vas 2003, 23, (5), 737-747.

83.

Yoshida, T.; Owens, G. K., Molecular determinants of vascular smooth muscle
cell diversity. Circ Res 2005, 96, (3), 280-91.

84.

Platt, J. L.; Nagayasu, T., Current status of xenotransplantation. Clin Exp
Pharmacol Physiol 1999, 26, (12), 1026-32.

85.

Nerem, R. M.; Seliktar, D., Vascular tissue engineering. Annu Rev Biomed Eng
2001, 3, 225-43.

86.

Minamino, T.; Miyauchi, H.; Yoshida, T.; Tateno, K.; Komuro, I., The role of
vascular cell senescence in atherosclerosis: antisenescence as a novel therapeutic
strategy for vascular aging. Curr Vasc Pharmacol 2004, 2, (2), 141-8.

87.

Rabkin, E.; Schoen, F. J., Cardiovascular tissue engineering. Cardiovasc Pathol
2002, 11, (6), 305-17.

88.

Stegemann, J. P.; Kaszuba, S. N.; Rowe, S. L., Review: Advances in vascular
tissue engineering using protein-based Biomaterials. Tissue Eng 2007, 13, (11),
2601-2613.

89.

McKee, J. A.; Banik, S. S.; Boyer, M. J.; Hamad, N. M.; Lawson, J. H.; Niklason,
L. E.; Counter, C. M., Human arteries engineered in vitro. EMBO Rep 2003, 4,
(6), 633-8.

46
90.

Poh, M.; Boyer, M.; Solan, A.; Dahl, S. L.; Pedrotty, D.; Banik, S. S.; McKee, J.
A.; Klinger, R. Y.; Counter, C. M.; Niklason, L. E., Blood vessels engineered
from human cells. Lancet 2005, 365, (9477), 2122-4.

91.

Kassem, M.; Abdallah, B. M.; Yu, Z.; Ditzel, N.; Burns, J. S., The use of hTERTimmortalized cells in tissue engineering. Cytotechnology 2004, 45, (1-2), 39-46.

92.

Kane, N. M.; Xiao, Q.; Baker, A. H.; Luo, Z.; Xu, Q.; Emanueli, C., Pluripotent
stem cell differentiation into vascular cells: a novel technology with promises for
vascular re(generation). Pharmacol Ther 2011, 129, (1), 29-49.

93.

Liu, J. Y.; Peng, H. F.; Andreadis, S. T., Contractile smooth muscle cells derived
from hair-follicle stem cells. Cardiovasc Res 2008, 79, (1), 24-33.

94.

Sundaram, S.; Niklason, L. E., Smooth Muscle and Other Cell Sources for Human
Blood Vessel Engineering. Cells Tissues Organs 2012, 195, (1-2), 15-25.

95.

Wang, A.; Tang, Z.; Li, X.; Jiang, Y.; Tsou, D. A.; Li, S., Derivation of Smooth
Muscle Cells with Neural Crest Origin from Human Induced Pluripotent Stem
Cells. Cells Tissues Organs 2012, 195, (1-2), 5-14.

96.

Gong, Z.; Niklason, L. E., Small-diameter human vessel wall engineered from
bone marrow-derived mesenchymal stem cells (hMSCs). FASEB J 2008, 22, (6),
1635-48.

97.

Chan-Park, M. B.; Shen, J. Y.; Cao, Y.; Xiong, Y.; Liu, Y.; Rayatpisheh, S.;
Kang, G. C.; Greisler, H. P., Biomimetic control of vascular smooth muscle cell
morphology and phenotype for functional tissue-engineered small-diameter blood
vessels. J Biomed Mater Res A 2009, 88, (4), 1104-21.

98.

Heydarkhan-Hagvall, S.; Chien, S.; Nelander, S.; Li, Y. C.; Yuan, S.; Lao, J.;
Haga, J. H.; Lian, I.; Nguyen, P.; Risberg, B.; Li, Y. S., DNA microarray study on
gene expression profiles in co-cultured endothelial and smooth muscle cells in
response to 4- and 24-h shear stress. Mol Cell Biochem 2006, 281, (1-2), 1-15.

99.

Gauvin, R.; Ahsan, T.; Larouche, D.; Levesque, P.; Dube, J.; Auger, F. A.;
Nerem, R. M.; Germain, L., A novel single-step self-assembly approach for the
fabrication of tissue-engineered vascular constructs. Tissue Eng Part A 2010, 16,
(5), 1737-47.

100.

L'Heureux, N.; Paquet, S.; Labbe, R.; Germain, L.; Auger, F. A., A completely
biological tissue-engineered human blood vessel. FASEB J 1998, 12, (1), 47-56.

101.

Norotte, C.; Marga, F. S.; Niklason, L. E.; Forgacs, G., Scaffold-free vascular
tissue engineering using bioprinting. Biomaterials 2009, 30, (30), 5910-7.

102.

Sengupta, D.; Heilshorn, S. C., Protein-engineered biomaterials: highly tunable
tissue engineering scaffolds. Tissue Eng Part B Rev 2010, 16, (3), 285-93.

47
103.

Ratcliffe, A., Tissue engineering of vascular grafts. Matrix Biol 2000, 19, (4),
353-7.

104.

Grenier, S.; Sandig, M.; Mequanint, K., Smooth muscle alpha-actin and calponin
expression and extracellular matrix production of human coronary artery smooth
muscle cells in 3D scaffolds. Tissue Eng Part A 2009, 15, (10), 3001-11.

105.

Grenier, S.; Sandig, M.; Mequanint, K., Polyurethane biomaterials for fabricating
3D porous scaffolds and supporting vascular cells. J Biomed Mater Res A 2007,
82, (4), 802-9.

106.

Li, J.; Ding, M.; Fu, Q.; Tan, H.; Xie, X.; Zhong, Y., A novel strategy to graft
RGD peptide on biomaterials surfaces for endothelization of small-diamater
vascular grafts and tissue engineering blood vessel. J Mater Sci Mater Med 2008,
19, (7), 2595-603.

107.

Dubey, G.; Mequanint, K., Conjugation of fibronectin onto three-dimensional
porous scaffolds for vascular tissue engineering applications. Acta Biomater 2011,
7, (3), 1114-25.

108.

Ma, P. X., Biomimetic materials for tissue engineering. Adv Drug Deliv Rev 2008,
60, (2), 184-98.

109.

Martin, I.; Wendt, D.; Heberer, M., The role of bioreactors in tissue engineering.
Trends Biotechnol 2004, 22, (2), 80-6.

110.

Nilsang, S.; Nehru, V.; Plieva, F. M.; Nandakumar, K. S.; Rakshit, S. K.;
Holmdahl, R.; Mattiasson, B.; Kumar, A., Three-dimensional culture for
monoclonal antibody production by hybridoma cells immobilized in macroporous
gel particles. Biotechnol Prog 2008, 24, (5), 1122-31.

111.

Nilsang, S.; Nandakumar, K. S.; Galaev, I. Y.; Rakshit, S. K.; Holmdahl, R.;
Mattiasson, B.; Kumar, A., Monoclonal antibody production using a new
supermacroporous cryogel bioreactor. Biotechnol Prog 2007, 23, (4), 932-9.

112.

Isenberg, B. C.; Williams, C.; Tranquillo, R. T., Small-diameter artificial arteries
engineered in vitro. Circ Res 2006, 98, (1), 25-35.

113.

Bilodeau, K.; Mantovani, D., Bioreactors for tissue engineering: focus on
mechanical constraints. A comparative review. Tissue Eng 2006, 12, (8), 2367-83.

114.

Riha, G. M.; Lin, P. H.; Lumsden, A. B.; Yao, Q.; Chen, C., Roles of
hemodynamic forces in vascular cell differentiation. Ann Biomed Eng 2005, 33,
(6), 772-9.

115.

Bilodeau, K.; Couet, F.; Boccafoschi, F.; Mantovani, D., Design of a perfusion
bioreactor specific to the regeneration of vascular tissues under mechanical
stresses. Artif Organs 2005, 29, (11), 906-12.

48
116.

Lee, A. A.; Graham, D. A.; Dela Cruz, S.; Ratcliffe, A.; Karlon, W. J., Fluid shear
stress-induced alignment of cultured vascular smooth muscle cells. J Biomech Eng
2002, 124, (1), 37-43.

117.

Zhao, S.; Suciu, A.; Ziegler, T.; Moore, J. E., Jr.; Burki, E.; Meister, J. J.;
Brunner, H. R., Synergistic effects of fluid shear stress and cyclic circumferential
stretch on vascular endothelial cell morphology and cytoskeleton. Arterioscler
Thromb Vasc Biol 1995, 15, (10), 1781-6.

118.

Davies, P. F., Flow-mediated endothelial mechanotransduction. Physiol Rev 1995,
75, (3), 519-60.

119.

Weinberg, C. B.; Bell, E., A blood vessel model constructed from collagen and
cultured vascular cells. Science 1986, 231, (4736), 397-400.

120.

Niklason, L. E.; Gao, J.; Abbott, W. M.; Hirschi, K. K.; Houser, S.; Marini, R.;
Langer, R., Functional arteries grown in vitro. Science 1999, 284, (5413), 489493.

121.

Niklason, L. E., Medical technology - Replacement arteries made to order.
Science 1999, 286, (5444), 1493-1494.

122.

Kolpakov, V.; Rekhter, M. D.; Gordon, D.; Wang, W. H.; Kulik, T. J., Effect of
Mechanical Forces on Growth and Matrix Protein-Synthesis in the in-Vitro
Pulmonary-Artery - Analysis of the Role of Individual Cell-Types. Circ Res 1995,
77, (4), 823-831.

123.

Jackson, Z. S.; Gotlieb, A. I.; Langille, B. L., Wall tissue remodeling regulates
longitudinal tension in arteries. Circ Res 2002, 90, (8), 918-25.

124.

Bissell, M. J.; Barcelloshoff, M. H., The Influence of Extracellular-Matrix on
Gene-Expression - Is Structure the Message. J Cell Sci 1987, 327-343.

125.

Lehoux, S.; Tedgui, A., Signal transduction of mechanical stresses in the vascular
wall. Hypertension 1998, 32, (2), 338-345.

126.

Lehoux, S.; Tedgui, A., Cellular mechanics and gene expression in blood vessels.
J Biomech 2003, 36, (5), 631-643.

127.

Streuli, C., Extracellular matrix remodelling and cellular differentiation. Curr
Opin Cell Biol 1999, 11, (5), 634-640.

128.

Humphries, M. J.; Travis, M. A.; Clark, K.; Mould, A. P., Mechanisms of
integration of cells and extracellular matrices by integrins. Biochem Soc T 2004,
32, 822-825.

129.

Glagov, S., Intimal hyperplasia, vascular modeling, and the restenosis problem.
Circulation 1994, 89, (6), 2888-2891.

49
130.

Tronc, F. o.; Mallat, Z.; Lehoux, S. p.; Wassef, M.; Esposito, B.; Tedgui, A., Role
of Matrix Metalloproteinases in Blood FlowÂ–Induced Arterial Enlargement :
Interaction With NO. Arterioscl Throm Vas 2000, 20, (12), e120-e126.

131.

Malda, J.; Rouwkema, J.; Martens, D. E.; le Comte, E. P.; Kooy, F. K.; Tramper,
J.; van Blitterswijk, C. A.; Riesle, J., Oxygen gradients in tissue-engineered
PEGT/PBT cartilaginous constructs: Measurement and modeling. Biotechnol
Bioeng 2004, 86, (1), 9-18.

132.

Radisic, M.; Deen, W.; Langer, R.; Vunjak-Novakovic, G., Mathematical model
of oxygen distribution in engineered cardiac tissue with parallel channel array
perfused with culture medium containing oxygen carriers. Am J Physiol-Heart C
2005, 288, (3), H1278-H1289.

133.

Radisic, M.; Malda, J.; Epping, E.; Geng, W. L.; Langer, R.; Vunjak-Novakovic,
G., Oxygen gradients correlate with cell density and cell viability in engineered
cardiac tissue. Biotechnol Bioeng 2006, 93, (2), 332-343.

134.

Schauf, C. L.; Moffett, D. F.; Moffett, S. B., Human Phisology, p.433. Mosby
College Publishing: 1990.

135.

Gerorge A. Truskey, F. Y., David F, Katz, Transport Phenomena in Biological
Systems. Prarson Prentice Hall: 2004; p 398-411.

136.

L.Fournier, R., Basic Transport Phenomena In Biomedical Engineering. Second
Edition ed.; Taylor & Francis: 2007; p 203-207.

137.

Riess, J. G., Oxygen carriers ("blood substitutes")--raison d'etre, chemistry, and
some physiology. Chem Rev 2001, 101, (9), 2797-920.

138.

Finucane, M. L.; Slovic, P.; Mertz, C. K., Public perception of the risk of blood
transfusion. Transfusion 2000, 40, (8), 1017-22.

139.

Lowe, K. C., Engineering blood: synthetic substitutes from fluorinated
compounds. Tissue Eng 2003, 9, (3), 389-99.

140.

Jahr, J. S.; Akha, A. S.; Holtby, R. J., Crosslinked, Polymerized, and PEGconjugated Hemoglobin-based Oxygen Carriers: Clinical Safety and Efficacy of
Recent and Current Products. Curr Drug Discov Technol 2011.

141.

Zuckerman, S. H.; Doyle, M. P.; Gorczynski, R.; Rosenthal, G. J., Preclinical
biology of recombinant human hemoglobin, rHb1.1. Artif Cells Blood Substit
Immobil Biotechnol 1998, 26, (3), 231-57.

142.

Spiess, B. D., Perfluorocarbon emulsions as a promising technology: a review of
tissue and vascular gas dynamics. J Appl Physiol 2009, 106, (4), 1444-52.

50
143.

Riess, J. G., Understanding the fundamentals of perfluorocarbons and
perfluorocarbon emulsions relevant to in vivo oxygen delivery. Artif Cells Blood
Substit Immobil Biotechnol 2005, 33, (1), 47-63.

144.

Riess, J. G., Perfluorocarbon-based oxygen delivery. Artif Cells Blood Substit
Immobil Biotechnol 2006, 34, (6), 567-580.

145.

Clark, L. C., Jr.; Gollan, F., Survival of mammals breathing organic liquids
equilibrated with oxygen at atmospheric pressure. Science 1966, 152, (3730),
1755-6.

146.

Sloviter, H. A.; Kamimoto, T., Erythrocyte substitute for perfusion of brain.
Nature 1967, 216, (5114), 458-60.

147.

Radisic, M.; Deen, W.; Langer, R.; Vunjak-Novakovic, G., Mathematical model
of oxygen distribution in engineered cardiac tissue with parallel channel array
perfused with culture medium containing oxygen carriers. Am J Physiol 2005,
288, (3, Pt. 2), H1278-H1289.

148.

Radisic, M.; Park, H.; Chen, F.; Salazar-Lazzaro, J. E.; Wang, Y. D.; Dennis, R.;
Langer, R.; Freed, L. E.; Vunjak-Novakovic, G., Biomirnetic approach to cardiac
tissue engineering: Oxygen carriers and channeled scaffolds. Tissue Eng 2006, 12,
(8), 2077-2091.

149.

Botchwey, E. A.; Dupree, M. A.; Pollack, S. R.; Levine, E. M.; Laurencin, C. T.,
Tissue engineered bone: measurement of nutrient transport in three-dimensional
matrices. J Biomed Mater Res A 2003, 67, (1), 357-67.

150.

Hidalgo-Bastida, L. A.; Thirunavukkarasu, S.; Griffiths, S.; Cartmell, S. H.; Naire,
S., Modeling and design of optimal flow perfusion bioreactors for tissue
engineering applications. Biotechnol Bioeng, 2012, 109, (4), 1095-1099

151.

Lesman, A.; Blinder, Y.; Levenberg, S., Modeling of Flow-Induced Shear Stress
Applied on 3D Cellular Scaffolds: Implications for Vascular Tissue Engineering.
Biotechnol Bioeng 2010, 105, (3), 645-654.

152.

Wang, Y. W.; Tomlins, P. E.; Coombes, A. G. A.; Rides, M., On the
Determination of Darcy Permeability Coefficients for a Microporous Tissue
Scaffold. Tissue Eng Part C-Methods 2010, 16, (2), 281-289.

153.

Mak, A. F., The Apparent Viscoelastic Behavior of Articular-Cartilage - the
Contributions from the Intrinsic Matrix Viscoelasticity and Interstitial FluidFlows. J Biomech Eng-T Asme 1986, 108, (2), 123-130.

154.

Buschmann, M. D.; Kim, Y. J.; Wong, M.; Frank, E.; Hunziker, E. B.;
Grodzinsky, A. J., Stimulation of aggrecan synthesis in cartilage explants by
cyclic loading is localized to regions of high interstitial fluid flow. Arch Biochem
Biophys 1999, 366, (1), 1-7.

51
155.

Steck, R.; Niederer, P.; Tate, M. L. K., A finite element analysis for the prediction
of load-induced fluid flow and mechanochemical transduction in bone. J Theor
Biol 2003, 220, (2), 249-259.

156.

Fritton, S. P.; Weinbaum, S., Fluid and Solute Transport in Bone: Flow-Induced
Mechanotransduction. Annu Rev Fluid Mech 2009, 41, 347-374.

157.

Dvir, T.; Levy, O.; Shachar, M.; Granot, Y.; Cohen, S., Activation of the ERK1/2
cascade via pulsatile interstitial fluid flow promotes cardiac tissue assembly.
Tissue Eng 2007, 13, (9), 2185-2193.

158.

Jaalouk, D. E.; Lammerding, J., Mechanotransduction gone awry. Nat Rev Mol
Cell Biol 2009, 10, (1), 63-73.

159.

Haemer, J. M.; Song, Y.; Carter, D. R.; Giori, N. J., Changes in articular cartilage
mechanics with meniscectomy: A novel image-based modeling approach and
comparison to patterns of OA. J Biomech 2011, 44, (12), 2307-2312.

160.

Price, C.; Zhou, X. Z.; Li, W.; Wang, L. Y., Real-Time Measurement of Solute
Transport Within the Lacunar-Canalicular System of Mechanically Loaded Bone:
Direct Evidence for Load-Induced Fluid Flow. J Bone Miner Res 2011, 26, (2),
277-285.

161.

Porter, B.; Zauel, R.; Stockman, H.; Guldberg, R.; Fyhrie, D., 3-D computational
modeling of media flow through scaffolds in a perfusion bioreactor. J Biomech
2005, 38, (3), 543-549.

162.

Hutmacher, D. W.; Singh, H., Computational fluid dynamics for improved
bioreactor design and 3D culture. Trends Biotechnol 2008, 26, (4), 166-172.

163.

Voronov, R.; VanGordon, S.; Sikavitsas, V. I.; Papavassiliou, D. V.,
Computational modeling of flow-induced shear stresses within 3D salt-leached
porous scaffolds imaged via micro-CT. J Biomech 2010, 43, (7), 1279-1286.

164.

Moaty Sayed, A.; Hussein, M.; Becker, T., An innovative lattice Boltzmann
model for simulating Michaelis–Menten-based diffusion–advection kinetics and
its application within a cartilage cell bioreactor. Biomech Model Mechanobiol
2009, (2), 141-151.

165.

Rauh, J.; Milan, F.; Gunther, K. P.; Stiehler, M., Bioreactor Systems for Bone
Tissue Engineering. Tissue Eng Part B-Reviews 2011, 17, (4), 263-280.

52

CHAPTER
3

3 TISSUE ENGINEERING SCAFFOLD FABRICATION,
EFFECTIVE DIFFUSION COEFFICIENT AND DYNAMIC CELL
CULTURE *
Overview: This chapter discuses scaffolds fabrication procedures with different polymer
concentrations, measuring oxygen diffusivity of scaffolds and screening them using their
morphology and oxygen diffusivity, seeding cells on tubular and disk shaped scaffolds,
culturing cell-seeded scaffolds in perfusion bioreactor, and analyzing the cultured cell
seeded scaffold using confocal microscopy, hematoxylin and eosin staining, and Western
blots.
Summary
Tubular and disk shaped poly (carbonate urethane) (PCU) scaffolds for in vitro tissue
engineering of vascular grafts were fabricated by a solvent casting and particulate
leaching method using NH4Cl as porogen. A better pore interconnectivity and oxygen
diffusion coefficient were resulted in scaffolds fabricated using 15% PCU in N,Ndimethylformamide (DMF). Human coronary artery smooth muscle cells (HCASMCs)
were seeded in these scaffolds and cultured up to 28 days under static or under flow
conditions in a perfusion bioreactor. For disk-shaped scaffolds, a better cell infiltration
depth and distribution was observed in the flow condition than static culture controls
whereas for cell seeded tubular scaffolds, higher number of cells were seeded and cells
*

A version of this chapter is submitted for publication and is currently under review.
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infiltrate into the tubular scaffolds and, a uniform distribution of cells throughout the
scaffold thickness was observed as shown by hematoxylin and eosin staining. Finally,
Western blot data suggested an upregulation of ECM proteins such as elastin. The results
demonstrate that scaffolds with low diffusivity were able to successfully integrate
HCASMCs as a step toward to the development of tissue engineered vascular grafts.

Keywords: Oxygen diffusivity, 3D scaffolds, perfusion bioreactor, tissue engineering

3.1 Introduction
Tissue engineering and regenerative medicine have emerged as promising methods for
addressing the increasing demand of small-diameter replacements for diseased
vasculature.1, 2 However, small-diameter arterial reconstructions (inner diameter <6 mm),
are not available to date.3 Natural or synthetic polymeric scaffolds have been widely used
in tissue engineering and regenerative medicine.4-6 The optimal scaffold structure is
selected based upon a combination of mechanical and physical factors, one of which is
the degree to which oxygen can diffuse though the scaffolds.7, 8 The ability of scaffold to
support cell growth throughout its thickness is affected by the scaffold oxygen diffusivity.
In vitro tissue maturation and immediately after surgical implantation until adequate
vascularisation has occurred, cells seeded into the scaffold mostly depend on the process
of diffusion for oxygenation.9-11 Therefore, the measurement of oxygen diffusivity in
scaffolds is a logical method for comparing the ability of scaffolds to support cell
viability, migration and infiltration within the scaffold.12, 13
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Tissue-engineered small diameter vascular grafts have the ability to sense hemodynamic
loading during dynamic culture, speciality when the culture media flows through the
lumen, and respond through mechanical and biological responses.2,

14, 15

Mechanical

stimulation of cells seeded in vascular tissue engineering scaffold promotes the
circumferential orientation of cells as well as the deposition of extracellular matrix.
Perfusion bioreactors also mimic the physiological conditions of coronary arteries and
can impose mechanical stimulation to cells and the hemodynamic loading during cultures
to engineer small diameter vascular grafts.16, 17
In the present study, scaffolds with different morphology were fabricated by varying the
PCU concentration, and were screened based on the measured effective oxygen
diffusivity. Based on morphology and oxygen diffusion coefficient, the best polymer
concentration for fabricating scaffolds was chosen. In view of developing small diameter
vascular grafts in vitro, HCASMCs were seeded on PCU scaffolds with disk and tubular
shapes. The cell seeded scaffolds were cultured in a perfusion bioreactor under
physiological flow conditions for several days. The advantage of dynamic culture in
regulating cell proliferation and distribution was evaluated by comparing the results with
static culture controls.

3.2 Materials and Methods
3.2.1 Fabrication of PCU scaffolds
3D scaffolds were fabricated by a solvent casting and particulate leaching method as
shown in Figure 3.1.18 Ground and sieved NH4Cl porogens (180-220 µm) were packed
into a tubular glass mold (6 mm outer diameter, 5 mm inner diameter and 8 cm height)
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using a pressure differential created from an air supply line (550 kPa) from the top
pushing and (0.014 kPa) suction applied from the bottom of the assembly. A medical
grade poly(carbonate urethane) (PCU) (Bionate® 55D) was obtained from DSM
Biomedical (Berkeley, CA). Different concentration of the PCU solution (15, 20, 25 and
30 wt%, dissolved in N,N-dimethylformamide) was subsequently poured over the
porogen bed and pressurized to infiltrate the porogen bed. Following this, the scaffolds
were removed from the assembly and the solvent was allowed to evaporate in a fume
hood. Finally, NH4Cl porogens were leached out using deionized water and, the scaffolds
were sectioned into 1.5 mm height disks using a microtome. This height (or thickness) of
the scaffolds was chosen to mimic the thicknesses of many soft tissues that are the subject
of tissue engineering.
Tubular scaffolds were made in the same apparatus but with different assembly; a
cylindrical stainless steel rod (4 mm diameter) was placed at the center of the tubular
glass mold and the NH4Cl porogens were packed in the space between the rod and the
glass mold. A polymer solution (15 wt %) was poured and pressurised to infiltrate into the
porogens bed; the mold is then removed from the assembly and placed in the fume hood
for 3 days for the solvent to evaporate completely. Finally, the scaffolds were removed
from the mold and the NH4Cl porogens were leached using deionized water (DI) and the
rod was removed from the center of the scaffold, the scaffolds were sectioned into 120
mm length using a microtome.
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Figure 3.1: Schematic diagram of the assembled, solvent casting and particulate
leaching, scaffold fabrication method and scaffolds fabricated from PCU.
3.2.2 Measuring dissolved oxygen and diffusion coefficient
The diffusion apparatus, built by the University Machine Shop, consisted of two 100 ml
chambers separated by the test scaffold, which was secured between the glass chambers
with stainless steel insert and rubber gasket o-rings (Figure 3.2). The opening between the
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two chambers had an area of 19.625 cm2. Each chamber was filled with 100 ml DI water.
The DI water in the donor chamber was saturated with ambient air; the DI water in the
receiver chamber was purged of dissolved oxygen by saturating with 100% nitrogen. To
approximate a well-mixed system, the solutions in each chamber were stirred throughout
the experiments. The oxygen concentration in the donor chamber was kept constant by a
continuous supply of ambient air. Both chambers were maintained at 37oC by an external
water bath. Fibre optic oxygen sensor model NeoFox (Ocean Optics, Dunedin, FL)
equipped with NeoFox software was used to measure dissolved oxygen. The oxygen
sensor was placed in the receiving chamber and measured dissolved oxygen every 10
seconds.

Figure 3.2: Schematic diagram of the diffusion cell apparatus
The flux of oxygen in the test scaffold can be calculated by performing a shell material
balance on the scaffold in one dimension leading to,
Accumulation = Input − Output + Production − Consumption

Vs

∂C
= J in z A − J out
∂t

z +∆z

A + PVs − GVs

(1)
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Where:
Vs is volume of the fraction of scaffolds where the mass balance was calculated
A is the cross sectional area of the scaffold
J in is the inlet flux crossing the area
J out is the outlet flux crossing the area
Z is the thickness of the scaffold, and
P and G are production and consumption of oxygen per volume of scaffold respectively.
At a steady state and with no consumption and production of oxygen in the scaffold, the
above equation reduces to diffusion in the z direction.
d 2C
Deff
=0
dz 2

(2)

Where Deff is the effective diffusivity.
With both donor and receiver chambers well-mixed, the boundary conditions for (2) are
the concentration of oxygen in the donor and receiver chambers. Thus,
=
BC1: C (0) C=
BC2 : C ( Z ) CR (t )
D
Where CD and CR are the concentration of oxygen in the donor chamber and receiver
chamber respectively.
The solution of the diffusion equation (2) will be,

 C (t ) − C D 
=
C  R
x+C D
Z



(3)
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Therefore, the flux in the scaffold will be,

∂C
 C (t ) − C D 
J=
− Deff
=
− Deff  R

∂z
Z



(4)

Since the mass balance in the receiving chamber will be unsteady state with no
consumption and production, equation (1) reduces to.

VR

∂CR (t )
= JA
∂t

(5)

Where, VR is the volume of the receiver chamber. Substituting the flux from (3) and
solving for the receiver chamber oxygen concentration gives:
 CR 0 − C D 
 = Deff t
 CR (t ) − C D 

ϕ ln 

where ϕ =

(6)

VR Z
A

Oxygen concentration was measured as a function of time for each scaffold and plotted as
a function of time. Using equation (4), the linear slope of the best fit line (as calculated by
the least-squares method using Sigma Plot Version 10) gives the effective diffusivity,
Deff , of the each scaffolds.

3.2.3 Cell culture in perfusion bioreactor
Primary human coronary artery smooth muscle cells (HCASMCs) and smooth muscle
growth media (SmGM®-2 BulletKit) were purchased from Lonza Walkersville Inc.
(Walkersville, MD, USA). Cells were cultured according to supplier’s instructions in
SmGM®-2, supplemented with 100 units/ml penicillin G sodium, and 100 µg/ml
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streptomycin sulphate (Invitrogen, Burlington, ON, Canada). All cultures were
maintained in a humidified incubator at 37ºC containing 5% CO2. HCASMCs were
passaged every 7 days at a split ratio of 1:3 and used between passages 4 to 7. Diskshaped scaffolds were affixed to glass coverslips using silicone grease, sterilized with
70% ethanol for 30 min and allowed to dry under germicidal UV light in tissue culture
hood for 30 min. After soaking the scaffolds in Hank's Buffered Salt Solution (HBSS,
Invitrogen, Burlington, ON, Canada), all scaffolds were coated with fibronectin (10
µg/cm2; Santa Cruz, CA, USA). Cells were seeded into the interstices of fibronectincoated PCU scaffolds at an initial cell density of ~3×104 cells/scaffold. After HCASMCs
attached to the scaffold for two days in static culture, the cell seeded scaffolds were
transferred to a perfusion bioreactor and cultured for 4 and 7 days. The culture medium
was purged through the porous cell seeded scaffold at a flow rate of 40 ml/min. A parallel
static HCASMCs cultures were carried out as controls for 4 days and 7 days where
culture medium was changed every other day.
A similar sterilization and preconditioning steps were used for tubular scaffolds but cells
were seeded into the lumen of fibronectin-coated PCU tubular scaffolds at an initial cell
density of ~1×106 cells/scaffold. HCASMCs were statically cultured in a slowly rotating
glass tube for two days to achieve uniform seeding and attachment to the scaffold. The
cell-seeded scaffolds were then transferred to a perfusion bioreactor and cultured for a
further 4 days, 7 days and 14 days at a medium flow rate of 40 ml/min. The calculated
wall shear stress was (τw= 1.74 dyns/cm2) and it is below the physiological maximum
shear stress in coronary arteries.10
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3.2.4 Fluorescence staining and laser scanning confocal microscopy
HCASMCs were fixed at room temperature for 1h with 4% (w/v) paraformaldehyde
(EMD Chemicals Inc.) and the tubular scaffolds then sectioned circumferentially using
microtome and axially using surgical blades. The cells were permeabilized for 10 min in
cation-free phosphate buffered saline (PBS) containing 0.1% (v/v) Triton X-100. Cells
were incubated for 1h at room temperature in 1% BSA/PBS containing AlexaTM Fluor
488-conjugated phalloidin (1:50 dilution), followed by three washes with PBS. DAPI
(300nM in PBS; Invitrogen, Burlington, ON, Canada) was used to label nuclei. Samples
were mounted on slides in SHUR/MountTM (TBS®, NC, USA) and analyzed with a Zeiss
LSM 410 confocal microscope (Zeiss, Canada) equipped with an argon/neon as well as a
UV laser.

3.2.5 Histologocal analysis using haematoxylin and eosin staining
HCASMCs cultured on PCU scaffolds were washed twice by ice cold PBS and embedded
in optimum cutting temperature (OCT) media (Tissue-Tek, VWR, Canada) in dry ice bath
and frozen to -80oC for 12h. The frozen blocks were transferred to cryotome crystat (20oC) and allowed the temperature of the frozen blocks to equilibrate to that of the
cryotome crystat. 50μm thickness samples were sectioned using cryotome and placed on
glass slides and the slides were heated to 30oC allowing the Tissue-Tek to melt. The
sectioned samples were carefully washed twice with PBS and fixed using 4% (w/v)
paraformaldehyde for 5 min, followed by two washes with DI water and then stained first
with hematoxylin and then with eosin (Sigma-Aldrich) with washes with DI water in the
intermediate and final stages of staining.
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3.2.6 Protein extraction and Western blot analysis
Following prescribed culture times, constructs were washed with ice cold PBS and
proteins were extracted using lyses buffer. The lysate was collected and spun in a
centrifuge and the supernatants were collected.

The amount of total protein was

quantified using BSA protein assay kit (Thermo Scientific, ON, Canada). 50 µg protein
samples were separated by 10% SDS-PAGE and subsequently transferred at 90 V for 1
hour at 4ºC to nitrocellulose membrane in a Tris-glycine buffer. Coomassie blue was used
to stain the total protein in gel. In addition the transfer efficiency and homogeneous
loading was assessed by Ponceau red stain. Nitrocellulose membranes were blocked with
5% nonfat dry milk in PBS and incubated overnight at 4ºC with primary antibodies
(monoclonal mouse anti-elastin at 1:200; anti-SM-α-actin and anti-GAPDH at 1:2000).
The blots were then labeled with Alexa 680- and IRDye 800-conjugated secondary
antibody (Invitrogen, Burlington, ON, Canada), and labeled proteins were visualized by
the Bio-Rad system (Bio-Rad Laboratories, Mississauga, Canada).

3.2.7 Statistical analysis
The results for the dissolved oxygen study and effective diffusion study were analyzed by
Student’s t-test. For all analyses, significance was assigned for p < 0.05.

63
3.3 Results
3.3.1 Scaffold fabrication
Tissue engineering scaffolds are required to have high porosity and pore
interconnectivity, and high surface area to volume ratio for cellular infiltration, matrix
remodelling, and nutrient transport to take place. In such scaffolds, cell seeding density
and distribution increases with pore interconnectivity. We therefore sought to examine the
effect of polymer concentration on porosity and interconnectivity of the scaffolds.
Different polymer concentrations (15, 20, 25, and 30 wt %, PCU dissolved in N,Ndimethylformamide) were used to make PCU scaffold and the resulting scaffold were
characterized using SEM. The strut thickness increased and pore interconnectivity
decreased as the amount of polymer increased in the polymeric solution as shown in
Figure 3.3. Scaffolds with lower polymer concentration were tried to fabricate but the
structures were fragile and difficult to handle. Therefore, 15 wt% polymer concentration
in DMF has been selected for further cell studies.
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Figure 3.3: SEM photomicrographs of PCU scaffolds fabricated from different
polymer concentrations. 15 wt % (A and B), 20 % wt (C and D) 25 % wt (E and F),
and 30 % wt (G and H) PCU concentration. Scale bars are 250μm for A, C, E G and
10μm for B, D, F and H.
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3.3.2 Effective oxygen diffusion coefficient in scaffolds
Fick's first law of diffusion on the passive transport of dissolved oxygen through the
thickness of clinically relevant scaffolds within an enclosed, well-mixed system was
applied to measure effective diffusion coefficient. Effective diffusivity measures the
resistance or the ability of a material to allow the passage of oxygen through it and Figure
3.4 show how the effective diffusivity can be calculated using the measured values of
dissolved oxygen in the receiver chamber by means of equation (6). Scaffolds fabricated
from 15 wt% polymer concentrations showed lower effective diffusivity than the other
concentrations (Figure 3.5). As the concentration of polymer used to making scaffold
increases the effective diffusivity increases as shown in the Figure 3.5. The higher
effective diffusivity in the scaffold will have higher cell retention and easier to supply
oxygen to the cells seeded on the scaffold. Therefore, scaffolds fabricated from 15 wt %
polymer concentration will have less resistance to oxygen supply to the seeded cells. This
result in combination with the SEM result suggests that 15% PCU concentration to be
suitable for cell culture and have been chosen for further cell culture studies.
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Figure 3.4: A) Oxygen concentration detected in the receiver chamber as a function
of time. Data used to calculate the effective oxygen diffusivity, Deff B) for 15% PCU,
C) 20% PCU, D) 25% PCU and E) 30% PCU.
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Figure 3.5: Effective oxygen diffusivity (cm2/s) in 3D scaffolds fabricated from
different PCU concentrations. Data are mean ±SD for 3 independent experiments.
NS means not significant.
3.3.3 Fluorescence staining and confocal microscopy
HCASMC-seeded disk-shaped scaffolds with 1mm thickness were cultured in a perfusion
bioreactor where the culture media flows through the scaffold. After 4 days of culture, the
cell-seeded scaffolds were imaged. A diffused red autofluorescence was observed due to
the PCU scaffolds helped to demonstrate that HCASMCs were penetrating into the
scaffold, but this did not affect the imaging process. HCASMCs were uniformly
distributed on the scaffold as shown in Figure 3.6. Comparing with the static culture
control, the cell density of the dynamic culture appeared to be similar. However, taking a
series of confocal images with 10 μm apart from the top of the scaffold to the point where
there are no more HCASMCs encountered, penetration depth to the scaffolds in dynamic
cultures was considerably higher than the static control cultures (230 μm vs. 120 μm)
suggesting that dynamic cultures improve cell penetration depths to the scaffolds whereas

68
this is not totally unexpected it does underscore the role of dynamic cultures to enhance
cell distribution and penetration depth.

Figure 3.6: Confocal microscopy images of HCASMCs cultured on disk shape PCU
scaffold in static (A-D) and dynamic (E-H) culture conditions. The top of the
scaffolds are shown in A and E whereas the bottom side are B and F, and the
orthogonal projections are C and G. Scale bar for all the images is 200μm.
In addition, HCASMCs seeded on tubular scaffolds were cultured for 4 days, 7 days, 14
days, and 28 days in a perfusion bioreactor where the culture medium flows through the
lumen of the tubular scaffolds. Cells were seeded from the lumen direction and cultured
in slowly rotating tubular glass for two days; this seeding approach with the high seeding
density helped to uniformly distribute throughout the scaffold from the lumen direction.
Figure 3.7 shows the confocal images of HCASMCs taken from different areas of the
scaffold. The cytoskeleton of the cells cultured in dynamic environment in the confocal
images are somewhat diffused in their quality. This is likely due to the topography effect
since the static cultures were conducted using porous disks whereas the dynamic cultures
were done using tubular scaffolds. In both cases, however, the high density of cells is
evident.
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Figure 3.7: Confocal microscopy images of HCASMCs cultured on tubular PCU
scaffolds in static (A, C, E and G) and dynamic (B, D, F and H) culture conditions
for 4 days (A&B) 7days (C&D) 14 days (E& F) and 28 days (G&H). Scale bar for
A,B,G and H is 200μm and for C,D,E and F is 100μm.
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3.3.4 Cross-sectional histological staining
Homogeneous distribution of HCASMCs in the tubular PCU scaffolds was confirmed by
means of histological staining with H & E as shown in Figure 3.8 which is consistent with
confocal images of the fluorescent staining. The high magnification of the H & E staining
shows a uniformly distributed of HCASMCs throughout the tubular PCU scaffold (B, D
and E). A high HCASMCs staining with the number of culture days was an indication of
cell proliferation.
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Figure 3.8: H&E staining of cross sections of HCASMCs seeded tubular PCU
scaffolds cultured under dynamic condition for 7 days (B and C), 14 days (E and F)
and 28 days (G and H). Bare scaffold was stained and imaged as a control (A and B).
Scale bar for A, C, E and G is 0.2mm and for B, D, F and H is 0.1mm.
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3.3.5 Western blot analysis
The total amount of protein from cell lysates cultured in dynamic and static conditions for
14 and 28 days was quantified using BSA protein assay. An equal amount of protein
(50μg) in each lane of the PAGE was run and the gel was stained using coomassie blue,
and subsequently imaged by Bio-RAD camera (Molecular imager Chemi DocTM). The
intensity of the protein bands in each lane is indicative of the relative amounts of protein
present. In the region of 50 kda to 100 kda, most proteins were upregulated in dynamic
cultures than in static culture controls as shown in Figure 3.9A. Therefore, further
staining for elastin (molecular weight ~66kda) and Smooth muscle α-actin (molecular
weight ~42kda) showed an upregulation in dynamic cultures than in static cultures as
shown in Figure 3.9 B. indicating a more synthetic phenotype of HCASMCs in dynamic
than static cultures. However, a more controlled and detailed experiments need be done
in order to get a better conclusive result.

Figure 3.9: Western blots of 14 days and 28 day cultures in static and dynamic
conditions coomassie blue staining and antibody staining of elastin, SM-α-actin and
GAPDH for 14 days culture.
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3.4 Discussion
The effective diffusivity measures the ability of a scaffold to allow the transport of
oxygen through it. In this study it is shown that 15 wt% polymer concentration has a
higher diffusion coefficient allowing higher amount of oxygen to be transported; these
results in higher cell viability, penetration depth into the scaffolds, and proliferation.
These findings suggest at least a partial dependence of oxygen transport on the polymer
concentration, porosity, and/or tortuosity of the scaffold. The tortuosity of the scaffold
were not directly measured in this study but instead incorporated into the effective
diffusivity variable.19 The SEM results also suggested 15 wt% polymer concentration
scaffolds resulted in higher pore interconnectivity. Whereas most studies on oxygen
diffusion through tissue engineering scaffolds focused on numerical analysis
approaches20-23, there are few studies related to the current work for experimentally
determining oxygen diffusivity. For example, Valentin et al24 measured oxygen
diffusivity of small intestine submucosa, urinary bladder submucosa, and Dacron®. Not
unexpectedly, their data indicated that each scaffold has unique oxygen diffusivity values
ranging from 2.4x10-6 cm2/s to 6.6x10-6 cm2/s, and these values were dependent on the
scaffold's ultrastructure. Dacron® had oxygen diffusivity which was one order magnitude
higher than the ECM scaffolds presumably due to the woven nature of it. In another
related study, Androjna et al25 measured the oxygen diffusivity of intestine submucosa,
human dermis (Alloderm®), and canine fascia lata and reported the effective diffusion
coefficients of all 3 ECM-based scaffolds to be to be in the order of 7x10-6 cm2/s to 4x105

cm2/s with the intestine submucosa tended to have the lowest oxygen. The differences in

the reported ranges are likely due to varying matrix structure porosity and tortuosity that
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is inherent in these tissues. In view of these cited studies, the oxygen diffusivity in all
PCU scaffolds (Figure 3.5) was comparable to natural ECM scaffolds. More importantly,
the oxygen diffusivity for 15wt% was better than ECM scaffolds but lower than Dacron®.
From this comparison it is possible to deduce that our scaffolds transports oxygen higher
than biological scaffolds but lower than synthetic scaffold Dacron®. To the best of our
knowledge, this study is the first to show oxygen diffusivity in PCU scaffolds as a
function of polymer concentration during the fabrication process.
HCASMCs penetration depth increased in dynamic cultures than the static culture
controls. This signifies higher cell population in the 3D scaffold, a finding that is also
supported by prior studies as Chan and Chong showed that perfusion systems increased
the oxygen profile in the scaffold, which in turn, increased the cell number with uniform
cell density.26 In addition, HCASMCs penetrated throughout the thickness of the tubular
scaffold as shown by the H&E staining. These results are consistent with literature reports
for other types of scaffolds. For instance, using H&E staining, Poot and coworkers
showed that VSMCs seeded into porous, tubular, flexible, and elastic poly(trimethylene
carbonate) scaffolds and cultured under perfusion had higher cell numbers. Interestingly
cell number peaked at day 7 and then decreased at day 14.3, 27 The mechanical properties
of the scaffolds also increased with culture time suggesting possible matrix deposition.
Although direct comparison with the above cited work cannot be done as we have not
specifically stained for ECM components in the histology study, reasonable inferences
can be drawn from the Western blot data (Figure 3.9B) that HCASMCs started expressing
elastin, one of the most important ECM component for vascular tissues. Previous studies
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from our laboratory also demonstrated the biosynthesis of both elastin and collagen by
HCASMC seeded to PCU scaffolds.28, 29
Notwithstanding the above, however, endothelialisation of the luminal surface of the
engineered vascular tissues is an additional requirement that must be satisfied from a
practical standpoint. Previously, the co-culturing of human coronary artery endothelial
cells and HCASMCs on scaffolds by using Matrigel coating was reported.2 Matrigelcoated layer not only was a structural mimic for the basement membrane (internal elastic
lamina), but also functioned to help chemically anchor other components, such as
laminins, collagen IV, nidogens (entactin) and heparan sulfate proteoglycan (perlecan).30
This approach could also be used for endothelialisation of the constructs described in the
present work. Furthermore, co-culture of endothelial cells and HCASMCs play a role in
the alignment of HCASMCs along the direction of flow.31 Moreover, co-culturing plays a
significant role in the phenotype regulation of HCASMCs. Our group showed evidences
that contact of HCASMCs and endothelial cells is required for the regulating smooth
muscle cell differentiation.32 .

3.5 Conclusions
A new way of screening scaffolds with effective diffusivity led to an observation that 15
wt% PCU scaffold could be used to engineer vascular grafts with good structures and
pore interconnectivity. Porous tubular and disk-shaped PCU scaffolds were seeded with
HCASMCs and subsequently cultured up to 28 days under flow conditions in a bioreactor
and static conditions. Both confocal and histological studies showed that dynamic culture
conditions significantly improved HCASMC penetration and uniform distribution
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throughout the scaffold as compared with static culture controls. The results of this study
indicated that a potentially useful tissue engineered vascular grafts can be fabricated by
dynamic culturing of human HCASMCs seeded in porous tubular PCU scaffolds.
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CHAPTER
4
4 EXPERIMENTAL AND MODELING STUDIES OF OXYGEN
TENSION IN VASCULAR TISSUE ENGINEERING WITH AND
WITHOUT AN OXYGEN CARRIER*

Overview: This chapter provides the use of perfluorodecalin (PFD) as oxygen carrier in
vascular tissue engineering. In doing so the amount of oxygen dissolved in PFD emulsion
was measured and the toxicity of PFD to vascular smooth muscle cells seeded on 3D
scaffold were examined and finally a mathematical model was developed for oxygen
profile in the lumen and 3D scaffold constructs.
Summary
The technology of vascular tissue engineering holds promise in the design of responsive
living conduits with properties similar to those of the native tissue. This approach,
however, constitutes an important engineering challenge because of the difficulty to grow
cells in high density, due to mass transfer limitations (delivery of nutrients and removal of
metabolic waste products). The major mass transfer challenge in tissue engineering arises
from the inability to deliver sufficient oxygen because of its low solubility and diffusivity
in culture media. In this work the utility of perfluorodecalin (PFD) as an oxygen carrier to
enhance oxygen delivery for the growth of human coronary artery smooth muscle cells

*

A version of this chapter is published: Seifu, D; Mequanint, K. (2011) Experimental and Modeling
Studies of Oxygen Tension in Vascular Tissue Engineering. Journal of Biomaterials and Tissue Engineering
1, 49-59
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(HCASMCs) seeded at high density on porous 3D polyurethane (PCU) scaffolds is
described. Furthermore, the diffusive and convective lumen and ablumen oxygen
distribution in engineered vascular tissue constructs is modeled. Both experimental and
modeling data demonstrated that oxygen tension on 3D scaffolds was improved by using
PFD as an oxygen carrier. Dissolved oxygen in the culture media with PFD was
significantly higher than the other fluids tested (p = 0.0017). Furthermore, HCASMC
number was significantly higher in the presence of PFD than in control scaffolds. Taken
together, these data suggest that PFD could be used as oxygen delivery vehicle in
vascular tissue engineering strategies.

Keywords
Vascular tissue engineering, oxygen transport, perfluorodecalin

4.1 Introduction
The strategy of in vitro vascular tissue fabrication is conceptually simple and appealing
yet it has proven to be a challenging engineering endeavour. Despite rapid advances made
in this field, success is still limited.

1

Compared with native tissues, one of the major

unsolved challenges in engineering three-dimensional (3D) tissues is the lack of
vascularization resulting in poor oxygen mass transfer.

Oxygen can be supplied to

vascular cells seeded into a tubular scaffold by radial diffusion from the lumen such that
the oxygen concentration decreases from the lumen and the outer limit of the construct.
Oxygen diffusion within the scaffold can be enhanced by increasing the overall diffusion
coefficient, decreasing the diffusion distance, and increasing convective transport. Since
tissue engineering is carried out in a bioreactor, hydrodynamic conditions can affect in
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vitro tissue formation in at least two ways:2 i) by direct effects of hydrodynamic forces on
cell morphology and function, and ii) by indirect flow-induced changes in mass transfer
of nutrients and metabolites. In static flask bioreactors, tissues are fixed in place and
cultured without hydrodynamic shear at tissue surfaces while relying on diffusional
oxygen transport for cell survival. In spinner flask bioreactors, tissues are fixed in place
and exposed to the steady turbulent flow of medium, which enhances oxygen mass
transfer but the level of mixing intensity required often surpasses the shear tolerance of
the cells.3 In a rotating-wall bioreactor, tissues are dynamically suspended in a laminar,
rotational flow field, and mass transfer is enhanced by laminar convection due to
construct settling. However, cell-seeded scaffolds often undergo repeated wall collisions
in rotating bioreactors, which disrupted tissue formation.4 Further, rotating-wall
bioreactor provided oxygen transfer only to the outer 100μm thick layer.5 Due to a tubular
scaffold requirement, none of the aforementioned bioreactor designs are suitable for
fabricating vascular tissues.
In order to improve oxygen transfer, oxygen generating scaffolds and perfluorocarbon
compounds as oxygen carriers has been proposed. For example, in cardiac and tracheal
tissue engineering, perfluorocarbons have been shown to improve construct oxygenation
without the above-mentioned adverse effects to the growing constructs.6-8 In this regard,
a steady state model for oxygen distribution in cardiac tissue constructs with parallel
channel array mimicking the in vivo capillary tissue bed and PFC compound oxygen
carrier was developed by Vunjak-Novakovic and co-workers.6 Despite this interesting
approach, the application of this model is limited to tissues such as cardiac and cartilage
because of the impracticality to create channel arrays within the cross section of vascular
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scaffolds. Further, at a wall-to-wall channel spacing of ~370μm, supply of sufficient
oxygen to seeded cardiomyocytes was not achieved. In vascular tissue engineering,
culture medium is pulsed and allowed to flow through the lumen which is anticipated to
cause transmural oxygen diffusion through the construct wall. However, in previous
studies the oxygen tension in the scaffold cross-section was neither predicted nor
measured.9,

10

Another reported approach to fabricate vascular tissues is a radial flow

culture system where oxygen dissolved in the culture medium entered into the lumen at
one end and forced out through the scaffold wall as transmural flow (by sealing the other
end of the lumen).11 However, the oxygen distribution in this study was not reported. In
fact, it can be argued that bioreactors for vascular tissue engineering have been studied
primarily for mechnotransduction rather than for oxygen transport studies.12, 13 Recently,
Bjork and Tranquillo14 reported a novel approach by combining both transmural and axial
flows to enhance oxygen transfer to rat vascular smooth muscle cells seeded into 3D
fibrin gel. Their data, however, suggest detrimental effects due to the lumenal pressure
needed to force transmural flow exceeding the burst pressure of the construct.
To overcome the aforementioned drawbacks while still at the same time delivering
sufficient oxygen, we propose a combined approach whereby perfluorodecalinsupplemented culture medium flows from both the lumen and ablumen sides of the
construct. In this manuscript we first present experimental evidences on the feasibility of
perfluorodecalin as an oxygen carrier. This is followed by a mathematical model for the
lumen and the tissue space oxygen distribution with perfluorodecalin as oxygen carrier in
a tubular scaffold both in static and in convective transport modes.
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4.2 Methods
4.2.1 Fabrication of 3D scaffolds
A medical grade poly(carbonate urethane) (PCU) (Bionate® 55D), kindly donated by the
Polymer Technology Group (Berkeley, CA), was used to fabricate 3D scaffolds by a
solvent casting and particulate leaching method as previously described.15 Briefly, ground
and sieved NH4Cl porogens (180-250 µm) were packed into a cylindrical infiltration
chamber, the polymer solution (15 wt% PCU dissolved in N,N-dimethylformamide) was
subsequently poured over the porogen bed and pressurized to infiltrate the porogen bed.
Following this, the scaffolds were removed from the assembly and the solvent was
allowed to evaporate in a fume hood. Finally, NH4Cl porogens were leached out using deionized water to obtain porous vascular scaffolds (Figure 4. 1A).
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Figure 4.1: SEM and digital image of PCU scaffold (A), tubular construct of porous
cell-seeded scaffold and mesh alignment of the model (B), perfusion bioreactor
digital image and schematic flow diagram including the setup (C)
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4.2.2 Dissolved oxygen measurements
Fibre optic oxygen probe model NeoFox (Ocean Optics, Dunedin, FL) equipped with
NeoFox software was used to measure dissolved oxygen. 2% perfluorodecalin (PFD)
(95% mixture of cis and trans; Sigma-Aldrich) was emulsified in the presence of smooth
muscle culture medium and continuously stirred at 37°C while the assembly was left open
to atmospheric air. A 300nm diameter oxygen probe was used to measure the dissolved
oxygen and a two point calibration, where 20.9% of oxygen at standard temperature and
pressure and 0% of oxygen in 100% nitrogen, was used.

4.2.3 Cell culture on 3D scaffolds
Primary human coronary artery smooth muscle cells (HCASMCs) and smooth muscle
growth media (SmGM®-2 BulletKit) were purchased from Lonza Walkersville Inc
(Walkersville, MD, USA). Cells were cultured according to supplier’s instructions in
smooth muscle growth media (SmGM®-2 BulletKit), supplemented with 100 units/mL
penicillin G sodium, and 100 µg/mL streptomycin sulphate (Invitrogen, Burlington, ON,
Canada). All cultures were maintained in a humidified chamber at 37ºC containing 5%
CO2. HCASMCs were passaged every 7 days at a split ratio of 1:3 and used between
passages 4 to 7. Scaffolds were sterilized with 70% ethanol for 30 min and allowed to dry
under UV light in tissue culture hood for 30 min. After socking the scaffolds in Hank's
Buffered Salt Solution (HBSS, Invitrgen, Burlington, ON, Canada) all scaffolds were
coated with fibronectin (10 µg/cm2; Santa Cruz, CA, USA). Cells were seeded onto
fibronectin-coated PCU scaffolds at an initial cell density of ~3×105 cells/scaffold.
HCASMCs were cultured for 7 days, 14 days, and 21 days.
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4.2.4 Cytotoxicity assay and cell number quantification
For colorimetric assays of the metabolic activity of viable cells, 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) (Invitrogen, Burlington, ON, Canada) was
used to quantify cytotoxicity following 24 h culture. MTT salts are reduced to a waterinsoluble formazan salt only by metabolically active cells allowing the assay to detect
viable cells exclusively. After it was solubilized, the formazan formed was quantified by
a plate reader at 570 nm (maximum absorbance). Negative control experiments were
carried out by adding MTT to 3D scaffolds and culture medium without cells. For cell
proliferation, cells were removed from the scaffolds according to our reported
methodology16 following specified culture times and counted using a hemocytometer.

4.2.5 Fluorescence staining and laser scanning confocal microscopy
HCASMCs were fixed at room temperature for 1 h with 4% (w/v) paraformaldehyde
(EMD Chemicals Inc.) and permeabilized for 10 min in cation free phosphate buffered
saline (PBS) containing 0.1% (v/v) Triton X-100. Cells were incubated for 1 h at room
temperature in 1% BSA/PBS containing Alexa Fluor 488-conjugated phalloidin (1:50
dilution), followed by 3 washes with PBS. DAPI (300nM in PBS; Invitrogen, Burlington,
ON, Canada) was used to label nuclei. Samples were mounted on slides in
SHUR/MountTM (TBS®, NC, USA) and analyzed with a Zeiss LSM 410 confocal
microscope (Zeiss, Canada) equipped with an argon/neon as well as a UV laser.
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4.2.6 Mathematical model for lumen oxygen profile
A cylindrical coordinate as shown in Figure 4.1B is used to model oxygen transfer in cell
seeded vascular scaffolds. A steady state oxygen balance in the scaffold lumen can be
described by the conservation equation:17
∂C Deff  ∂  ∂C  ∂ 2C 
VZ [1 − L=
+ LM d ]
 r
+

r  ∂r  ∂r  ∂Z 2 
∂Z

(1)

Where VZ is the culture medium velocity, L is the PFD volume fraction, Md is the oxygen
dissociation constant of PFD, Z is the axial direction, r is the radial direction, Deff is the
effective oxygen diffusion constant and C is the oxygen concentration. Equation (1) is
subject to the following boundary and initial conditions:

 ∂C (r , Z ) 
 ∂C (r , z ) 
B.C1: 
0 ; B.C2: J =
; I.C: C (r , 0) =
Co
− Deff 
 =

 ∂r r 0=
 ∂r r R
=
The flow of the medium in the lumen is assumed to be fully developed and, the velocity
profile is given by;
  r 2 
=
Vz 2Vm 1 −   
 R 



(2)

Where Vm is the average fluid velocity.
In order to calculate the effective diffusion coefficient in equation (1), the following
expression was used.18

 γ −1  
=
De Da 1 + 3 
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γ
2
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(3)
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Where γ =

C p Dp
Ca Da

; Da is the aqueous phase diffusivity, Ca dissolved oxygen in aqueous

phase, D p is diffusivity of PFD, and C p is dissolved oxygen in PFD.

4.2.7 Mathematical model for cell-seeded scaffold oxygen profile
A homogeneous cell-seeded scaffold, where culture medium flows both from the lumen
and ablumen, was considered to model the oxygen profile in the tissue space. The flux of
oxygen from the lumen and ablumen were calculated with a consumption rate and with
the effective diffusivity. A steady state differential equation for cell-seeded scaffold will
have both the diffusion term and a consumption term (as represented by MichaelisMenten kinetics) in accordance with following equation:

V C
∇ ( Dt ∇ ( C ) ) =max
Km + C

(4)

The boundary conditions for equation 4 are:
 ∂C (r , Z ) 
J lumen = Dt 

 ∂r r
=

 ∂C (r , Z ) 
and J ablumen = Dt 

 ∂r r
R=
in

Rout

Dt is the effective oxygen diffusivity in the tissue space and, the values were adopted
from Riley et al 19 based on Monte-Carlo simulation. For cell volume fraction
0.04<ϕ<0.95 in the scaffold:
 D 
Dt
=1 − 1 − cell  1.727φ − 0.8177φ 2 + 0.09075φ 3
Do
Do 


(

)

(5)
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Where Dcell is the diffusivity of oxygen in cells, Do is the diffusivity of oxygen through
the interstitial fluid space and ϕ is the volume fraction of cells.

4.2.8 Model parameters
The mathematical model equations presented above were implemented for the set of
experimental conditions summarized in Table 4.1. In order to maintain the wall shear
stress within the reported physiological values of normal coronary arteries 20 and to show
the effect of flow rates, a flow rate of 15mL/min (τwall = 0.65 dynes/cm2), 23 mL/min
(τwall = 1 dynes/cm2), and 40mL/min (τwall = 1.74 dynes/cm2) were used. Average
velocity was calculated based on cross-section area of the lumen. Maximum oxygen
consumption (Vmax) for vascular smooth muscle cells was taken from literature.21 The
volume fraction of the circulating PFD molecules was 2%. In addition to the lumen
oxygen profile, the model was used to predict oxygen concentration profiles for vascular
tissue constructs of clinically relevant thickness (1mm), flow rates, and cell density
ranging from 106cell/mL to 5x106cell/mL. The cells were assumed to be uniformly
distributed throughout the pores of the 3D scaffold. The corresponding volumetric
maximum oxygen consumption rate (Vmax per unit volume) was calculated for the
respective cell numbers. Culture medium at the inlet of the construct was assumed to be
fully saturated with atmospheric oxygen with an oxygen partial pressure of 160 mmHg.
The partial pressure of oxygen for culture medium supplemented with PFD was measured
to be 220 mmHg using the reported value of oxygen solubility in PFD 37oC.22
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4.2.9 Numerical solutions
The solutions for the model equations were obtained using the PDE toolbox built in
MatLab R2009a utilizing finite element model. In order to use the toolbox, the boundary
conditions were modified as follows.
•


n ( De∇C ) =
J wall (Neumann condition). Since the generalized Neumann condition

in the PDE toolbox software is n ( De∇C ) + qC = g, and C depends on r in this



J wall ( r )
problem, this boundary condition was expressed as n ( De∇C ) =
•

C = 220 mmHg at the left end of the cylinder (Dirichlet condition).

•

The cylinder axis at r = 0 is not a boundary in the original problem but in 2D

treatment, due to symmetry, n ( De∇C ) =
0.

Solving equations (1) and (4) took up to 1933 successful steps, zero failed attempts, 4053
evaluated functions, 511 LU decomposition, 4053 solutions of linear systems with
computation times ranging from 4 to 7 min.

4.2.10 Statistical analysis
The results for the dissolved oxygen study were analyzed by analysis of variance
(ANOVA). Student’s t-test was used to analyze the cytotoxicity of PCU scaffold and
proliferation of HCASMC as a function of culture time. For all analyses, significance was
assigned for p < 0.05.
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4.3 Results and discussion
4.3.1 The effect of PFD on dissolved oxygen in HCASMCs culture medium, cell
spreading and cell viability.
In this work the feasibility of PFD to enhance oxygen delivery to vascular smooth muscle
cells seeded into 3D scaffolds was investigated. The rationale for choosing PFD was
twofold. Firstly, while dissolving high level of oxygen (ca. 42.3 ml per 100 ml of O2), it is
reported that PFD has longer tissue retention time which holds promise for a clinical
application compared with the most widely used perflubron

23

. Secondly, unlike

Oxygent™ whose primary content is perflubron, PFD is not investigated as oxygen
carrier for tissue engineering applications. Because in vitro cell culture data using PFD is
not reported, it was first investigated if this molecule could be a candidate to enhance
oxygen delivery in vascular tissue engineering. Figure 4.2 shows the measured dissolved
oxygen concentration in PFD-supplemented HCASMC culture medium and other fluids
at 37oC and atmospheric pressure. There was no statistical significance between DI water,
PBS and HCASMC culture medium. The oxygen solubility values in these fluids were
comparable to the calculated value using Henry's law. However, in comparison to the
variety of biological fluids tested, there was a highly significant difference when 2% PFD
was added in HCASMC culture medium (p=0.0017). This data shows that by
incorporating 2% PFD in culture media, there was a significant increase of dissolved
oxygen at 37oC. Dissolved gases are transported by perfluorinated compounds due to
increased solubility in accordance with Henry's Law. The increase is attributed due to the
existence of loose, non-directional van der Waals interactions leading to low cohesive
energy densities, which facilitates mutual solubilization of oxygen in the fluorine
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compound that is bound to the surface of the emulsion.24 To evaluate the possible
cytotoxic effect of 2% PFD on cultured HCASMC, cells were cultured on coverslips with
and without PFD for up to 7 days. The phase-contrast microscopy images (2D cultures)
and confocal microscopy images (3D scaffolds) presented in Figure 4.3 demonstrated that
the morphology and spreading of cells were not affected by the presence of PFD. The
MTT assay data presented in Figure 4.4 also affirmed that 2% PFD was not cytotoxic to
HCASMCs. Although data is not available for vascular smooth muscle cells,
perfluorocarbon emulsions even at low concentrations are in general considered to be
cytotoxic and inhibitor to proliferation in cultured human fibroblast cells 25, 26. Figure 4.4,
on the other hand, demonstrates excellent cell viability which could be due to the
differences in the type of perfluorocarbon used in our study and in the above-cited
studies. Based on the feasibility data presented herein, a fixed 2% PFD was used to
investigate cell growth in 3D scaffolds and to predict oxygen tension in our mathematical
model.

Figure 4.2: Dissolved oxygen partial pressure in different fluids measured at 37 oC.
Oxygen concentration was measured using fibre optic probe. Data are mean ± SD
for experiments conducted in triplicate. * indicates statistical significance.
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Figure 4.3: Phase contrast images of HCASMC, cultured without PFD
supplemented medium (A, C and E) and with PFD (B, D and F) for 1 days, 2 days
and 7 days. Confocal microscopy images of HCASMCs cultured on 3D scaffolds
with PFD (H) and without PFD supplemented medium (G).
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4.3.2 HCASMC proliferation when seeded to 3D scaffolds with 2% PFDsupplemented medium.
In order to rationalize the modeling approach and to examine the effect of 2% PFD in
culture medium, HCASMC proliferation on 3D scaffolds was investigated. The results
presented in Figure 4.5 demonstrated that cell number significantly increased following 7
days, 14 days and 21 days of culture with 2% PFD (p < 0.05). Since equal numbers of
cells were seeded on all scaffolds and that both scaffolds and PFD were not cytotoxic, the
significant increase in cell numbers as a function of time indicates that an environment
conducive for cell growth was established by providing sufficient oxygen tension as will
be shown in the mathematical model in the next section.

Figure 4.4: HCASMC viability using MTT assay on 3D PCU scaffold cultured with
and without PFD supplemented medium. Data are mean ±SD for experiments
conducted in triplicate. * indicates statistical significance
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Figure 4.5: HCASMC proliferation on 3D scaffolds with and without PFD
supplemented medium for 7 days (A) 14 days (B) and 21 Days (C). Data are
mean±SD for experiments conducted in triplicate. * indicates statistical significance.
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4.3.3 Numerical solution for oxygen profiles in static 3D cultures.
Diffusion and convection are the two main mass transfer mechanisms in cell seeded 3D
scaffolds. To establish a baseline, the oxygen profile in both the lumen and tissue space
was first simulated for static cultures where the lumen is filled by a stagnant culture
medium. Since cells are seeded only to the scaffolds, there is no lumen oxygen
consumption in the model equation so the lumen oxygen profile represents this fact.
Therefore, it is expected that the oxygen distribution within the lumen is governed only
by diffusion. Due to symmetry, only half of the lumen was modeled and, a representative
lumen oxygen profile is shown in Figure 4.6A, from which it can be inferred that the
oxygen partial pressure decreased rapidly as we move from the two ends of the scaffold
lumen to the centre along the axis of the scaffold. The oxygen flux from the lumen by
diffusion will be consumed by cells in the scaffold. At a cell density of 2.5x106cells/mL
which was used to obtain the data for Figure 4.6A, the oxygen profile at the midpoint of
the scaffold lumenal length (Z = 0) reached zero. Figure 4.6A also shows that at any
cross section of the lumen the concentration of oxygen is minimum at the interface
between the scaffold and culture media and maximum at the center which follows the flux
as shown by the direction fields (indicated by a series of red arrows in the radial
direction). To study the effect of cell density, the lumen-scaffold interface oxygen
concentration was plotted (Figure 4.6B). The model indicates that from all cell densities
shown, oxygen diffusion from the lumen was sufficient only for low cell seeding density.
Above 1.5x106 cells/ml diffusion alone was not able to deliver oxygen for cell survival as
indicated by the corresponding partial pressure that drops to zero. It is to be recognized
that a minimum oxygen concentration above 20 mmHg must be maintained in the lumen
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to avoid a necrotic environment in the tissue space.27, 28 In addition to the lumen oxygen
profile, the tissue space oxygen profile with and without PFD supplement was modeled
and, the results are presented in Figure 4.7. Without PFD, oxygen partial pressure
dropped to below 20 mmHg at a scaffold depth of ≈ 0.15 mm (Figures 4.7 A &C).
Despite the enhancement in the oxygen penetration depth into the tissue space to about
0.4mm, the presence of 2% PFD does not appear to be sufficient to supply enough
oxygen to seeded HCASMCs as shown by the rapid depletion of oxygen with increased
scaffold thickness (Figures 4.7 B &C).
Table 4.1: Model parameters used to predict oxygen concentration profiles in a
vascular tissue constructs oxygenated with PFD supplemented culture medium.
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Figure 4.6: Model prediction of oxygen profile in the lumen at static culture
condition in 3D plot (A) and a plot of lumen-scaffold interface oxygen partial
pressure for different cell densities (B).
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Figure 4.7: Oxygen profile in the scaffold (tissue space) at static condition in 3D plot
with and without PFD supplemented medium (B, C) and a plot of cross sectional
oxygen partial pressure for different cell densities (C).
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4.3.4 Numerical solution for oxygen profiles in 3D cultures with convection
The second part of the modeling study was done to include convective mass transfer to
the diffusion. We assumed that the medium flow to be fully developed laminar flow
which is reasonable because many practical bioreactors including ours have long tubing
often forming loops from the pulse generator to the tissue construct (Figure 4.1C). Due to
symmetry, only half of the lumen was modeled and; the concentration of oxygen on the Z
direction is maximum at the inlet and minimum at the exit (Figure 4. 8A&B). In addition
to that, Figure 4.8B shows that at any cross section of the lumen, the concentration of
oxygen is minimum at the interface between the scaffold and culture medium and
maximum at the center in the direction of the flux. The model prediction shows that the
best result for oxygen profile in the lumen with 2% PFD is obtained when the flow rate is
40 ml/min and HCASMCs are seeded at a density of 2.5x106 cells/ml. Although it is
possible to increase the flow rate to enhance oxygen transfer either for higher cell density
than the one assumed herein in the scaffolds or for longer scaffolds than the one utilized
in this model, it should be pointed out that this can be done at the detriment due to
excessive wall shear stress. At a lumen radius of 3mm, the wall shear stresses calculated
in this model varied from 0.65 dynes/cm2 (corresponding to 15 ml/min medium flow) to
1.74 dynes/cm2 (corresponding to 40 ml/min medium flow) which are physiologically
relevant.20

To model the oxygen profile in the tissue space, a homogeneous cell-seeded scaffold
where culture medium flows both from the lumen and ablumen was considered. The
rationale for the ablumen flow was to mimic the vasa vasorum that supply oxygen to
smooth muscle and fibroblast cells within the media and adventitia of arteries. The
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bioreactor in our laboratory is also able to supply essential nutrient from the lumen and
the ablumen.

Figure 4.8: Oxygen profile in the lumen and in the scaffold at a flow condition. A 3D
representation of the oxygen partial pressure in half of the lumen (A), a plot of
lumen-scaffold interface oxygen partial pressure for different cell densities (B), a 3D
plot of the oxygen partial pressure in scaffold (C) and a plot oxygen partial pressure
across the cross section of the scaffold for different cell densities (D).
The flux of oxygen from the lumen and ablumen was calculated with a Michaelis-Menten
consumption rate and with effective diffusivity and was subsequently used as a boundary
condition to solve the oxygen profile in the tissue space. The numerical solution of the
PDE given in equation 1 plotted in Figures 4.8 C&D showed that the concentration of
oxygen is maximum at the scaffold-lumen interface and minimum at the centerline of the
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scaffold wall thickness. At concurrent lumen and ablumen flow rate of 40 ml/min, culture
medium supplemented with 2% PFD provided the necessary oxygen for up to, 3.75x106
cells/ml. Although the vascular smooth muscle cells density assumed in this study is
relatively lower compared with the physiologic values,29 it is deemed to be an acceptable
density for vascular tissue engineering. The plots in Figure 4.8D showed that the oxygen
partial pressure continuously decreased as one moves from the lumen-scaffold interface
(thickness = 0) to the scaffold centreline (thickness = 0.5). This was followed by a
continuous upward swing towards the outer scaffold space, reaching a maximum at
thickness = 1mm. The oxygen partial pressure values at thickness = 0 and at thickness =
1mm are not the same because of the differences in the outer and inner radius of the tissue
space used in the model. Since the total flux is fixed based on oxygen consumption,
oxygen transfer from the ablumen is higher than the lumen due to increased radius (and
hence surface area).
One key design element in tissue engineering is maintaining adequate mass transfer while
at the same time providing local conducive environment to the differentiated state of
seeded cells. The mechanism of oxygen transport and consumption in cells is an
important problem which has received considerable attention in recent years30-32. Hoare
and coworkers33 reported a window of operation to engineer vascular constructs with
sufficient oxygen delivery based on convection and diffusion from the lumen. Whereas
their approach captured the practical aspect of cell density in the construct space and the
wall shear stress (calculated based on the given critical flow rates), the model
underestimates both the wall thickness (0.2mm used in the model vs. 0.5mm-1mm for
typical coronary arteries) and the oxygen consumption of vascular smooth muscle cells.
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Specifically, the oxygen consumption data used in their model is an order magnitude
lower than the oxygen demand of vascular smooth muscle cells.14,

21

Due to these

underestimations, we believe that their prediction will fall short of the physiologic
relevance in both the wall thickness of the vascular constructs and the oxygen
consumption of vascular smooth muscle cells. Although the oxygen consumption rate
data in the work of Bjork and Tranquillo14 is realistic for vascular smooth muscle cells,
the pressure required to deliver oxygen via transmural flow was detrimental to the
growing tissue constructs thus limiting their efforts. In addition, the 0.2 mm wall
thickness used is lower than typical coronary arteries. By combining a practical wall
thickness (1 mm), experimentally determined oxygen consumption rate of vascular
smooth muscle cells, and physiologic wall shear stress, the present study suggests that
without oxygen carrier molecules, fabrication of tissue engineered vascular constructs
may be limited by oxygen mass transfer. This, in turn, could limit the initial mechanical
functionality and subsequent in vivo function of grafts of clinically relevant size.
Because of the poor solubility of oxygen in culture media at physiologic temperature, its
delivery represents one of the most critical issues in engineering clinically relevant
functional 3D tissues.31 While cells consume approximately six mole of soluble oxygen
per mole of glucose, the solubility of oxygen in typical culture media is an order
magnitude lower than the available glucose. As a result, engineered tissues that are more
than approximately 100-μm-thick and supplied with nutrients solely by diffusion may
have insufficient oxygen transport to the cells. It has been widely acknowledged that the
supply of oxygen becomes critically limiting for the in vitro culture of 3D tissues.34 This
is demonstrated by early studies showing that cellular spheroids larger than 1 mm in
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diameter generally contain a hypoxic and necrotic center, surrounded by a rim of viable
cells.35 Similar observations beyond depths of 0.25 mm were reported for hepatocytes,
osteoblasts and cardiomyocytes cultured on 3D scaffolds under static conditions.36-38 As a
result, tissue engineered constructs frequently have an inhomogeneous structure
consisting of a dense layer of cells and extracellular matrix concentrated along the
periphery, and a necrotic interior region.39 Because engineered blood vessels should be at
least 0.5 mm in wall thickness, oxygen mass transfer limitations represent a critical
design issue to be addressed for tissue functionality.
The metabolic oxygen consumption rate is generally a function of concentration. The
most common oxygen consumption rate expression (per unit volume per unit time) is the
Michaelis-Menten equation:
Oxygen consumption rate =

Vmax C
Km + C

The above equation reduces to zero-order consumption when the available oxygen
concentration is high (i.e. C  K m ) and to first-order kinetics for low oxygen
concentrations (i.e. C  K m ). The zero-order limit is often considered as a reasonable
approach because the condition C  K m is easily met physiologically. However, in tissue
engineering, available oxygen quickly depletes and it is equally likely that the condition
C  K m to be satisfied. In this study the model is tested with all these possibilities
(Figure 4.9). It is evident that zero-order consumption led to the local oxygen
concentration to drop to unacceptably low levels, even with 2% PFD. In many instances
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oxygen delivery to cells is bounded by zero-order and first-order consumption rates in
accordance with the Michaelis-Menten equation.

Figure 4.9: A plot oxygen partial pressure across the cross section of the scaffold for
2.5×106 cell/ml density for zero order, Michaelis-Menten and first order kinetics.
medium flow rate was 40 ml/min.
Despite oxygen delivery challenges, tissue engineering of vascular constructs have been
achieved using different bioreactors.10,

14, 29

In many of these instances, the wall shear

stress due to increased flow rates inadvertently compromised the integrity of the tissue by
altering cellular responses. In the present work the use of 2% PFD as oxygen carrier
allow us to deliver oxygen to tissue constructs at physiologic shear forces and flow rates.
Further we made use of realistic vascular tissue diameter and wall thickness to model the
oxygen profile concentration within the engineered tissue. This is expected to improve
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design optimization in order to ensure long-term viability and functional property
maintenances for human implantation.

4.4 Conclusions
One unsolved problem in tissue engineering is overcoming hypoxia in thick, threedimensional engineered tissues, which is caused by the diffusional limitations of oxygen
in the centre of the scaffold and lack of internal vasculature to facilitate mass transfer. In
order to combat this obstacle, a steady state mathematical model was developed to
simulate transport of oxygen in both the lumen and the tissue space. In this study, a
mathematical model was developed using PFD as oxygen carrier in 3D tissue engineered
scaffold. Dissolved oxygen concentration significantly increased in the presence of PFD
in a culture media. Vascular smooth muscle cell viability was not affected by the presence
of the PFD and; cell proliferation with PFD was significantly higher than those without
PFD. Our data suggest that PFD emulsion increase the oxygen tension in 3D tissue
engineered scaffolds and enhanced oxygen delivery to cells.
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CHAPTER
5

5 TISSUE ENGINEERING SCAFFOLDS CONTAINING
EMBEDDED FLUORINATED-ZEOLITE OXYGEN VECTORS *

Overview: This chapter provides the use of fluorinated Zeolite particles as oxygen
delivery vector. Fluorinated Zeolite particles were prepared and examined for their
ability to dissolve oxygen in aqueous media. The toxicity of these particles was examined
and embedded into 3D PCU scaffolds. Finally their effect as an oxygen vector was
investigated by culturing vascular smooth muscle cells on fluorinated Zeolite embedded
3D PCU scaffolds.
Summary
Efficient oxygen supply is a continued challenge for the fabrication of successful tissue
engineered constructs with clinical relevance. In an effort to enhance oxygen delivery, the
feasibility of fluorinated-zeolite particles that are embedded into 3D polyurethane
scaffolds as novel oxygen vectors is reported herein. First, 1H, 1H, 2H, 2Hperfluorodecyltriethoxysilane was successfully coupled to zeolite framework particles to
examine the dose-dependent dissolved oxygen concentration. Following this, the
fluorinated-zeolite (FZ) particles were embedded into 3D tissue engineering polyurethane
scaffolds. The data demonstrated an even distribution of FZ particles into 3D scaffolds

*

A version of this chapter is published: Seifu, D.G; Isimjan, T.T; Mequanint, K. (2011) Tissue engineering
scaffolds containing embedded fluorinated-zeolite oxygen vectors. Acta Biomaterialia 7: 3670–3678
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without affecting the scaffold porosity and pore sizes. Human coronary artery smooth
muscle cells (HCASMCs) proliferation on FZ-containing polyurethane (PCU-FZ)
scaffolds was significantly higher than the control scaffolds (p = 0.05). Remarkably, cell
infiltration depths on PCU-FZ scaffolds was doubled compared with PCU control
scaffolds. Taken together, these data suggest the potential of PCU-FZ scaffolds for tissue
engineering with enhanced oxygen delivery to cells.

Keywords: Oxygen delivery, 3D scaffolds, zeolite nanoparticles, tissue engineering

5.1 Introduction
The biomedical applications of nanomaterials such as drug delivery systems, diagnostic
imaging agents, and microfluidics are drawing attentions due to the unique features they
present.1-3 Tissue engineering strategies benefited from advances made in nanomaterials
specifically on the utility of carbon nanotube scaffolds.4-7 Although progress has been
made to fabricate engineered tissues in vitro using both conventional and nanomaterials,
the inability to deliver sufficient oxygen to the growing constructs (due to its poor
solubility in culture media) remained to be a formidable task.8, 9 This is exemplified by
early studies showing that cellular spheroids generally contain a hypoxic and necrotic
center surrounded by a rim of viable cells.10,

11

Similar observations were reported for

osteoblasts, hepatocytes, and cardiomyocytes cultured in 3D scaffolds under static
conditions.12-14
Previous attempts to overcome oxygen transfer limitations in tissue engineering relied on
perfusion bioreactors where oxygen dissolved in the culture medium diffuses to the
scaffold’s interior. However, the high flow rate required to maintain adequate oxygen
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concentration for cell viability often surpasses the shear stress tolerance of the cells.15, 16
In an alternative, the use of perfluorocarbon (PFC) emulsions as an oxygen carrier in
tissue engineering has been investigated where the oxygen unloading of PFC emulsion
was facilitated by the increased surface area provided by the emulsion droplet size.17 In
spite of the reported encouraging data, the high density of the PFC emulsion meant that
the droplets could easily settle either in the culture well or in the medium reservoir.18
This, in turn, implies that PFC emulsions may not be effective oxygen carriers. In view of
the above, it would be advantageous if the oxygen carrier molecules could be bound to
the scaffold. In this regard, Harrison and coworkers reported calcium peroxide-based
oxygen generating particles incorporated into the scaffold to provide a sustained oxygen
release over an extended period of time.19 The reaction products, namely Ca(OH)2 and
H2O2 are, however, strong base and strong oxidizing agents respectively, in which the
drawback could outweigh the benefit. This drawback is exemplified by a recent study
which demonstrated significant reduction of fibroblast viability when calcium peroxide
was incorporated to polycaprolactone fibrous scaffolds.20 In addition, the calcium
peroxide loaded to the scaffold will eventually be depleted making this approach limited
to short term cultures.
In this study, a novel approach of enhanced oxygen delivery to cells seeded in 3D
scaffolds by incorporating fluorinated porous zeolite particles as an integral part of the
scaffolds is reported.
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5.2 Materials and Methods
5.2.1 Preparation of fluorinated-zeolite (FZ)
Analytical grade chemicals and reagents used for the preparation of FZ were purchased
from Sigma–Aldrich (Milwaukee, WI) unless otherwise stated and, were used as
received. Zeolite Y powder was crystallized from a synthetic gel with a molar
composition of: 4 Na2O : 1 Al2O3 : 6 SiO2 : 200 H2O : 5 (TMA)2O , where (TMA)2O
designates tetramethylammonium hydroxide (25%, Merck KGaA, Darmstadt, Germany)
used as a organic template or structural directing agent. The synthetic gel was prepared by
dissolving appropriate amounts of sodium aluminates (NaAlO2) as Al source and sodium
hydroxide (NaOH) to a mixture of water and (TMA)2O under vigorous stirring until a
homogenous solution was obtained. Silica gel (as Si source) was then added to the
resulting solution in a 30 ml Teflon reactor and mixed for 10 min. The resulting synthetic
gel was aged for 48 h under static condition. The zeolite Y product was allowed to
crystallize from the aged gel at 100oC in an oven for 48 h. When the reaction was
completed, the pure crystalline zeolite powders were recovered from the suspension by
centrifugation at 10,000 rpm. The solid particles were re-dispersed in deionized water and
centrifuged again. The washing and centrifugation process were repeated three times. The
solid products were dried at 50oC for 24 h, followed by calcinations at 500oC for 5 h in a
programmable furnace with the heating and cooling rate of 1oC/min to activate the zeolite
by removing the organic residues and water. The resulting zeolite-Y was then fluorinated
with 1 wt % methanol solution of 1H, 1H, 2H, 2H-perfluorodecyltriethoxysilane (PTES)
for 1 h, filtered and then heated at 140oC for an additional 1 h. The particle sizes of the
zeolite were in the range of 850 nm-1000 nm.
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5.2.2 Fabrication of PCU-FZ scaffolds
A medical grade poly(carbonate urethane) (PCU) (Bionate® 55D) was kindly donated by
the Polymer Technology Group (Berkeley, CA). 3D scaffolds were fabricated by a
solvent casting and particulate leaching method as previously described21 with some
modifications. Ground and sieved NH4Cl porogens (180-250 µm) were packed into a 6
mm diameter cylindrical infiltration chamber together with 2 wt% FZ nanoparticles and,
the polymer solution (15 wt% PCU dissolved in N,N-dimethylformamide) was
subsequently poured over the porogen bed and pressurized to infiltrate the porogen bed.
Following this, the scaffolds were removed from the assembly and the solvent was
allowed to evaporate in a fume hood. Finally, NH4Cl porogens were leached out using
deionized water and, the scaffolds were sectioned into 1.5 mm height disks using a
microtome. This height (or thickness) of the scaffolds was chosen to mimic the
thicknesses of many soft tissues such as cartilages,22 skin,23 cardiac,24 and blood vessels25
that are the subject of tissue engineering . Two different control scaffolds, namely PCU
scaffolds without FZ particles and, scaffolds that contained non-fluorinated zeolite
particles, were fabricates in a similar way.

5.2.3 Dissolved oxygen measurement
Fibre optic oxygen sensor model NeoFox (Ocean Optics, Dunedin, FL) equipped with
NeoFox software was used to measure dissolved oxygen. The sensor uses ruthenium (II)
complexes suspended in a support matrix and attached at the tip of the fiber optic cable.
When excited by a light emitting diode at 475 nm, the ruthenium complex fluoresces and
emission occurs at 620 nm. When the excited ruthenium complex encounters an oxygen
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molecule, the emission is quenched allowing the intensity of the fluorescence to be
related to the oxygen concentration. Accordingly, the more oxygen that is present, the
lower the emission intensity and vice-versa. In the absence of oxygen, the maximum
fluorescent intensity of emitted light is observed. FZ nanoparticles at concentrations of
0.5%, 1%, and 2% were suspended in deionized water and continuously stirred at 37oC
while the assembly was left open to atmospheric air. Deionized water and non-fluorinated
Zeolite particles (non-FZ) suspended in deionized water (at 2% concentration) were used
as controls. A 300 nm diameter oxygen probe was used to measure the dissolved oxygen
following a two point calibration with 20.9% of oxygen at standard temperature and
pressure and 0% oxygen in 100% nitrogen.

5.2.4 Chemical composition and morphological studies of FZ and PCU-FZ scaffolds
The crystallinity of the zeolite particles was measured by powder X-ray diffractometer
(XRD), (Rigaku RINT 2500, Tokyo, Japan) with Cu K radiation (λ = 1.54
Å) at 40 kV
and 50 mA with a scan rate of 0.02 degrees per second over a 2θ ranges of 2° to 40°. The
zeolite particle pore size and surface area were determined by a BET (Brunauer, Emmett
and Teller) method using nitrogen adsorption–desorption isotherms by means of an
ASAP2010 instrument (Micromeritics Instrument Corporation, Norcross, GA). The
zeolite pore size was also calculated by the advanced Barrett–Joyner–Halenda (BJH)
method using the adsorption-desorption branches of the isotherms. Prior to these
measurements, the samples were degassed at 170oC for 24 h in vacuum. To investigate
the surface and cross-section morphology of scaffolds, high-resolution scanning electron
microscope (SEM) images were captured using model FIB/SEM LEO 1540XB
microscope (Carl Zeiss, Oberkochen, Germany) operating at electron beam voltage of 1
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kV. Scaffolds were affixed on a carbon sample holder and were coated with 4 nm osmium
vapor before imaging. In addition, energy dispersive X- ray spectroscopy (EDX) was
used to map the elemental composition and distribution within the scaffolds. Elemental
compositions of the fluorinated zeolite praticles and the scaffolds were determined by Xray photoelectron spectroscopy (XPS, Perkin Elmer, Waltham, MA) and EDX. The XPS
analyses were carried out with a Kratos Axis Ultraspectrometer using a monochromatic
Al Kα source (15 mA, 14 kV).

5.2.5 Scaffold porosity measurements
Mercury porosimetry measurements were made using an Autopore IV porosimetery
(Micromeritics, Norcross, GA). Samples of PCU and PCU-FZ scaffolds were cut into
cylindrical disks with 1.5 mm hight and 6 mm in diameter, before placing in the
penetrometer. Care was taken to place adequate sample in the penetrometer to achieve
significantly measurable intrusion volumes while maintaining unimpeded access by the
mercury to the entire surface of the samples. Prior to mercury intrusion, the penetrometer
was degassed to approximately 4kPa to remove air from the system. Mercury filling of
the penetrometer was performed at 3.5kPa. Logarithmically spaced data points were taken
at pressures ranging from 0.35kPa to 410kPa. An equilibrium intrusion rate threshold was
set at 0.003 mL/g/s. For purposes of data analysis, the surface tension of mercury and the
intrinsic contact angle with the scaffolds were taken to be γHg = 480 N/m and θ = 140o
respectively. Average pore areas were corrected for deformation of the scaffold under
elevated pressure, as described elsewhere 26.
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5.2.6 Cell culture on PCU and PCU-FZ scaffolds
Primary human coronary artery smooth muscle cells (HCASMCs) and smooth muscle
growth media (SmGM®-2 BulletKit) were purchased from Lonza Walkersville Inc.
(Walkersville, MD, USA). Cells were cultured according to supplier’s instructions in
smooth muscle growth media (SmGM®-2 BulletKit), supplemented with 100 units/ml
penicillin G sodium, and 100 µg/ml streptomycin sulphate (Invitrogen, Burlington, ON,
Canada). All cultures were maintained in a humidified incubator at 37ºC containing 5%
CO2. HCASMCs were passaged every 7 days at a split ratio of 1:3 and used between
passages 4 to 7. Cylindrical scaffolds were affixed to glass coverslips using silicone
grease, sterilized with 70% ethanol for 30 min and allowed to dry under germicidal UV
light in tissue culture hood for 30 min. After socking the scaffolds in Hank's Buffered Salt
Solution (HBSS, Invitrgen, Burlington, ON, Canada), all scaffolds were coated with
fibronectin (10 µg/cm2; Santa Cruz, CA, USA). Cells were seeded into the interstices
fibronectin-coated PCU and PCU-FZ scaffolds at an initial cell density of ~3×104
cells/scaffold. This relatively low seeding densisty was chosen such that we can verify
cell infiltration depths into the scaffold interstices without cells outgrowing from the
scaffold surface as is the case in high-densisty seeding. HCASMCs were cultured for 4
days, 7 days, and 14 days and the culture medium was exchanged every other day.

5.2.7 Cytotoxicity assay
For colorimetric assays of the metabolic activity of viable cells, 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) (Invitrogen, Burlington, ON, Canada) was
used to quantify cytotoxicity and cell proliferation. MTT salts are reduced to a water-
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insoluble formazan salt only by metabolically active cells allowing the assay to detect
viable cells exclusively. After it was solubilized, the formazan formed was quantified in a
conventional plate reader at 570 nm (maximum absorbance). PCU-FZ and PCU scaffolds
were affixed in 96-well culture plates using silicone grease and sterilized with 70%
ethanol for 30 min. After drying for 30 min, the scaffolds were soaked in HBSS and
~3x104 HCASMCs were seeded and cultured for 24 h in a humidified chamber at 37ºC
containing 5% CO2. After changing the culture media, 10μL of MTT was added to each
well and incubated for 4 h. Then 100μL of sodium dodecyl sulphate (Invitrogen,
Burlington, ON, Canada) was added and mixed thoroughly and finally incubated for an
additional 4 h before reading its absorbance at 570nm using a multiplate reader. Two
different negative control experiments were carried out: (i) by adding MTT to the culture
medium only and, (ii) by adding MTT to the scaffolds only to rule out the possibility that
trapped reagents in the scaffold may contribute to background reading.

5.2.8 Immunofluorescence staining and laser scanning confocal microscopy
HCASMCs were fixed at room temperature for 1 h with 4% (w/v) paraformaldehyde
(EMD Chemicals Inc.) and permeabilized for 10 min in cation free phosphate buffered
saline (PBS) containing 0.1% (v/v) Triton X-100. Cells were incubated for 1 h at room
temperature in 1% BSA/PBS containing AlexaTM Fluor 488-conjugated phalloidin (1:50
dilution), followed by three washes with PBS. DAPI (300nM in PBS; Invitrogen,
Burlington, ON, Canada) was used to label nuclei. Samples were mounted on slides in
SHUR/MountTM (TBS®, NC, USA) and analyzed with a Zeiss LSM 410 confocal
microscope (Zeiss, Canada) equipped with an argon/neon as well as a UV laser.
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5.2.9 Statistical analysis.
The results for the dissolved oxygen study were analyzed by analysis of variance
(ANOVA). Student’s t-test was used to analyze the cytotoxicity of PCU-FZ scaffold and
proliferation of HCASMC as a function of culture time. For all analyses, significance was
assigned for p < 0.05.

5.3 Results and Discussion
5.3.1 Characterization of fluorinated zeolite (FZ)
In the biomedical field, the use of particles as contrasting agents in imaging and as drug
delivery vehicles is an emerging area.1-3 In order to expand their potential application for
tissue engineering scaffolds with oxygen binding capability, porous fluorinated zeolite
particles with a pore size of ~7.4 Å and surface area of 750 m2/g were prepared. The
schematic framework structure of zeolite (Y-type) is shown in Figure. 1A. This zeolite
was fluorinated with a methanol solution of hydrolyzed 1 wt% 1H, 1H, 2H, 2Hperfluorodecyltriethoxysilane (PTES) (Figure 5.1B). When PTES is attached on the
surface of zeolite particles, it forms a monolayer at a temperature of 140oC. The XRD
patterns of the current particles are presented in Figure 5.1C and, are consistent with
literature data.27 Furthermore, the fluorination step did not affect the crystalline peaks of
the zeolite particles.
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Figure 5.1: (A) Framework structure of Zeolite Y, (B) chemical structure of PTES,
and (C) XRD pattern of the prepared fluorinated Zeolite Y.
5.3.2 Dissolved oxygen concentration in FZ particles
Measurements of dissolved oxygen concentration in the presence of different weight
percentage of FZ particles were conducted in deionized water at 37oC and atmospheric
pressure using a fiber optic oxygen sensor (Figure 5.2). There was no statistical
significance between the control (0% FZ) and 0.5% FZ. Similarly, there was no statistical
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significance in the amounts of oxygen dissolved between 1% and 2% FZ (p<0.05).
However there was a significant difference between the other groups of FZ contents
(p<0.05). These data show that by incorporating 2% FZ in deionized water, there was a
significant increase of dissolved oxygen at 37oC. It seems that there is a minimum
threshold of 1% FZ that is needed to increase the dissolved oxygen concentration in a
significant way. On the other hand, when non-fluorinated zeolite particles were
suspended in deionized water, there was no difference in the amount of dissolved oxygen
compared with deionized water alone. As will be shown shortly in Table 5.2, 73% of the
fluorinated molecules that are responsible for dissolving oxygen were located at the
surface of the zeolite particles which, in turn, were exposed to the bulk liquid. This is
contrary to conventional fluorinated emulsions where the oxygen is trapped in the core of
the particle. Consequently, the probe measures total dissolved oxygen concentrations
present both in water and in the fluorinated particles. Thus the increased oxygen
concentration

is

attributed

to

the

presence

of

1H,

1H,

2H,

2H-

perfluorodecyltriethoxysilane at the surface of the zeolite particles. Gases are transported
by perfluorinated compounds due to increased solubility in accordance with Henry's law.
The increase is attributed due to the existence of loose, non-directional van der Waals
interactions leading to low cohesive energy densities,28 which facilitates mutual
solubilization of oxygen in the fluorine compound that is bound to the surface of the
particles that are embedded in the scaffold. Oxygen solubility also reflects the very low
intermolecular interactions (fluorine’s low polarizability translates into low van der Waals
forces) within a FZ monolayer. Unlike a chemical binding situation known in
hemoglobin, solubilized oxygen can be rapidly and extensively extracted from the
perfluorinated molecules when needed. Although FZ above 2-wt% could have been
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theoretically incorporated in our experiments, inclusion of more than 2% particles into the
scaffolds was not possible because the fabricated scaffolds lacked mechanical integrity.

Figure 5.2: Dissolved oxygen concentrations in de-ionized water at 37oC, in the
presence of non-fluorinated Zeolite particles, and in the presence of different weight
percentages of fluorinated Zeolite particles. Oxygen concentrations were measured
using a fiber optics probe. Data are means ± SD for experiments conducted in
triplicate. * indicates statistical significance at p < 0.05.
5.3.3 FZ modified scaffolds characterization
Tissue engineering scaffolds are required to have high porosity and pore
interconnectivity, and high surface area to volume ratio for cellular infiltration, matrix
remodelling, and nutrient transport to take place. Using MicroCT imaging, our group
have previously reported PCU scaffolds having a porosity of 84%.29 Therefore the effect
of FZ incorporation on the porosity of PCU scaffolds was examined. Mercury
porosimeter analysis of both control scaffolds and those incorporating FZ particles
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showed porosities of 90% (Table 5.1). These results indicate that the pore area and
porosity of the scaffolds was not affected by FZ incorporation.

Table 5.1: Mercury porosimetry analysis data for PCU and PCU-FZ scaffolds.

The pore-size distribution obtained from the mercury prosimetry is shown in Figure 5.3.
It is clearly shown that the addition of the FZ particles did not affect the pore size
distribution. It also shows that the differential intrusion volume, which is an indicator of
the scaffold porosity, was the same for both PCU and PCU-FZ scaffolds. The porosity
data presented in Table 5.1 affirms this observation. The intrusion and subsequent
extrusion cycles during the mercury prosimetry experiments resulted in negligible
hysteresis indicating that scaffold compression at the operating pressures was minimal.
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Figure 5.3: Scaffold pore size distribution obtained by mercury porosimetry for
PCU and PCU-FZ scaffolds plotted as a function of differential and cumulative
intrusion volumes
The SEM images of scaffolds presented in Figure 5.4A-D shows that the pores were
open, interconnected, and well-defined. This is needed for cell infiltration and
unrestricted cell-cell communications. All scaffolds had similar pore sizes, ranging from
50-200 μm which are ideal for many tissue engineering applications. At high
magnification, the embedded FZ particles (≈1µm size) in the FZ -containing scaffolds are
evident (see insert in Figure. C) indicating that the salt leaching process did not affect the
particles whereas, at the same magnification, control PCU scaffolds showed smooth
scaffold struts and walls. Furthermore, these images show that the FZ particles were
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uniformly distributed along the struts and walls of the scaffolds without affecting the
macroporosity of the scaffolds.

Figure 5.4: SEM and EDX analyses of fluorinated Zeolite-modified PCU scaffolds.
(A) Control PCU scaffolds; (B) FZ-modified PCU scaffolds; (C) high magnification
images of the struts in FZ-modified PCU scaffolds (inset: high magnification image
showing the FZ particles); (D) SEM image of the area where EDX mapping was
undertaken; (E–J) EDX elemental mapping for (E) Al, (F) C, (G) F, (H) O, (I) Si and
(J) a combination of all elements; (K) EDX spectrum for FZ-modified PCU
scaffolds. Images were captured using a Zeiss LEO 1530 SEM microscope at
working voltages of 1 keV for high magnifications and 5 keV for low magnifications.
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Given that we have used a solvent casting and particulate leaching method to fabricate
these scaffolds, it is remarkable that the FZ particles were not affected during the NH4Cl
leaching step in water. This is very likely to be the result of better interfacial adhesion
between the polymer and the FZ particles facilitating improved entrapment of the FZ
particles. Strong adhesive forces between a zeolite coating layer and bone biomaterials
have been recently suggested to their enhanced in vitro performance.30 Additional
evidences for the successful incorporation and uniform distribution of the fluorinated
particles into 3D scaffolds came from elemental mapping using EDX (Figure 5.4 E-K).
The qualitative distribution of Al, Si, and F, which are only expected from the FZmodified 3D scaffolds demonstrate this even distribution (Figure 5.4 E-J).
The elemental compositions of the FZ particles and the scaffolds were further studied
using XPS. The position of the fluorine 1s peaks at 686.8 eV in the XPS spectrum is
indicative of fluorine substitution in the SP3 carbon framework. As can be seen in Table
2, the FZ particles had 40% fluorine and 23% carbon. Because the FZ particles are largely
inorganic in their composition, the carbon atom is relatively low. The PCU scaffold
which is used as a control had no fluorine peak at 686 eV and, a carbon atom of 81% is
considerably high. This is not unexpected since the constituents of PCU control scaffolds
are only carbon, oxygen, and nitrogen (as hydrogen cannot be detected using XPS).
However, PCU scaffolds fabricated by incorporating fluorinated zeolite particles had very
strong fluorine 1s peak with atomic percentage of 29% which was 73% of the fluorine
found in the fluorinated zeolite particles. XPS results not only indicate the incorporation
the fluorinated zeolite particles in the PCU scaffolds, but also revealed that most of the
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fluorinated zeolite were on the surface of the scaffolds which is crucial for oxygen supply
to seeded cell.

Table 5.2: XPS analysis of the fluorine content in FZ particles, PCU scaffolds and
PCU-FZ scaffolds. The numbers in brackets indicate the corresponding binding
energies.

5.3.4 HCASMC growth on PCU and PCU-FZ scaffolds
In a previous publication from our laboratory,31 it was shown that PCU scaffolds were not
cytotoxic to HCASMC and, that cells proliferated without any phenotype modulation.32
In view of this, the current study used PCU scaffolds as controls to evaluate HCASMC
viability on PCU-FZ scaffolds using MTT assay. Figure 5.5A showed that PCU scaffolds
incorporating fluorinated zeolite particles had no cytotoxic effect to seeded HCASMC.
This cytotoxicity data is consistent with literature reports suggesting the biological
activity of silicate and aluminosilicate zeolites having no cytotoxic effects to cells.30, 33, 34
The use of zeolite framework as a biocompatible and anticorrosive coating for titanium
alloy biomaterials demonstrated pluripotent mouse embryonic stem cells having higher
adhesion and proliferation on the 3D zeolite microstructure surface compared with a 2D
glass surface, indicating that the zeolite coatings were highly cytocompatible.30 Zeolites
have also been demonstrated to be a safe oral contrast agent for clinical magnetic
resonance imaging without significant adverse effects.35 Moreover, zeolites are good
adjuvant in anticancer therapy,36 improve skin-whitening by inhibiting melanin
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production in a dose-dependent manner,34 and demonstrated to decrease TiO2photosensitized reactive oxygen species in cultured fibroblasts.33

To examine the effect of fluorinated zeolite incorporation to 3D scaffolds, HCASMC
proliferation on PCU-FZ scaffolds was investigated. The results presented in Figure 5.5B
demonstrated that cell number significantly increased for 4 days and 7 days of culture for
PCU-FZ scaffolds (p<0.05). As an additional control experiment, cells were also seeded
into scaffolds with embedded non-fluorinated zeolite particles to rule out the effect of
surface topography due to the embedded particles. No difference compared with PCU
scaffolds was observed. Given that we have seeded equal number of cells on both
scaffolds and that both scaffolds were not cytotoxic, the significant increase in cell
numbers on PCU-FZ indicates that these scaffolds provided an environment conducive
for cell growth by providing sufficient oxygen. The apparent decrease is cell number at
day 4 culture is explained as follows. The data at day 1 reflects the initial seeding density.
The slight decrease in cell number at day 4 is likely attributed due to cell retention. Then,
the retained cells started to proliferate which is clearly demonstrated at day 7. Although
this study suggested an increase cell number for PCU-FZ scaffolds for up to 7 days
culture, it is not known at this stage if the amount of dissolved oxygen will be sufficient
to support longer culture times or higher cell seeding density that we have used. Further
studies will be required to address these possibilities.
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Figure 5.5: HCASMC (A) viability and (B) growth on PCU, PCU-FZ, and PCU-nonFZ 3-D scaffolds. Data are means ± SD for experiments conducted in triplicate.
*Indicates statistical significance.
5.3.5 HCASMC morphology and depth of infiltration on PCU-FZ scaffolds
In addition to the cytotoxicity and cell growth studies, information on the morphology
and infiltration depths of HCASMCs on 3D PCU-FZ scaffolds is essential. Labeling for
F-actin and DNA were used to examine cellular morphology following 4, 7 and 14 days
of culture. Figure 5.6 shows that HCASMCs attached and spread on both scaffolds
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regardless zeolite incorporation. At higher magnifications, cells making larger contacts on
both scaffold surfaces are evident.

Figure 5.6: Confocal microscopy images of HCASM cultured on PCU and PCU-FZ
scaffolds for 4 days(A, B, G, H), 7 days (C, D, I, J) and 14 days (E, F, K, L).
HCASMC attached to both PCU and PCU-FZ scaffolds had similar morphologies
but the cell density appeared to be higher on the PCU-FZ scaffolds. Scale bars: (A),
(C), (E), (G), (I), (K), 200 μm; (B), (D), (F), (H), (J), (L), 100 μm.
Given that these images are taken at a single plane (cell seeded side), insight into which
cells infiltrated to the scaffolds is limited. To visualize cell distribution into the center of
the scaffold, confocal stacks of images were taken such that each image is separated by
10 μm from the next. The procedure continued to deeper sections of the scaffolds until no
more cells were detected. The images collected were then binned into 4 depth ranges
namely, 0-50 µm; 50-100 µm; 100-150 µm; 150-200 µm and, the results are presented in
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Figure 5.7.

Interestingly, cells on PCU scaffolds infiltrated only to about 100 µm

whereas on PCU-FZ scaffolds, infiltration depths doubled to 200 µm during 7 days of
culture. Since HCASMCs were seeded only on one side of the scaffolds; the observed
infiltration depths are unlikely to be due to seeding techniques. Furthermore, both
scaffolds had similar pore sizes and porosity as measured by mercury porosimetery
(Table 5.2). Therefore, it is believed that enhanced HCASMCs infiltration and uniform
distribution on PCU-FZ scaffolds is due to the available oxygen at deeper sections of the
scaffolds. Since cell growth data (Figure 5.5) showed PCU-FZ scaffolds promoted
HCASMCs proliferation, infiltration appeared to be driven primarily by localized
proliferation rather than coordinated cellular migration.

133

Figure 5.7: The effect of FZ incorporation on HCASMC spreading and infiltration
after 4, 7 and 14 days of culture. (A, B, E, F, K, L) PCU scaffolds; (C, D, G–J, M–P)
PCU-FZ scaffolds. Orthogonal views of the confocal images are shown at the
bottom. Scale bar: 200 μm.
Tissue engineering has been motivated by the need to develop novel treatment options for
the functional restoration of diseased tissues. Despite this, overcoming the diffusion
barrier that limits the delivery of essential nutrients is a primary obstacle in the
development of engineered tissues with clinical relevance. As a result, engineered tissues
that are more than 100 μm-thick and supplied with nutrients solely by diffusion may have
insufficient transport to and from the cells37 since the cell microenvironment is dependent
on both nutrient and oxygen availability within the scaffold and the surrounding medium.
Because of the poor solubility of oxygen in culture media, its delivery represents the most
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challenge in engineering functional 3D tissues. While cells consume approximately the
same molar amount of soluble oxygen as glucose, the solubility of oxygen in typical
culture media is an order magnitude lower than the available glucose. Conversely, an
excess of oxygen in the medium surrounding the cells without an appropriate carrier such
as hemoglobin, achieved by using pure oxygen instead of air or by increasing gas
pressure induces the presence of free radicals, which are cytotoxic.38 Oxygen delivery
strategies such as perfusion bioreactors have been the most widely investigated where
flow-induced hydrodynamic conditions were anticipated to increase the mass transport of
oxygen without cell and tissue damage.39 However, as stated earlier, the high flow rate
required to maintain an adequate oxygen concentration for cell viability often surpasses
the shear tolerance of the cells.15,

16

As an alternative, perfluorocarbon emulsions have

been studied as a means to deliver oxygen to seeded cells.18,

40

In these studies, the

perfluorocarbon compound was emulsified and added to cell culture medium. However
their high density (~1.5 to 2 times that of water) make the emulsified particles to easily
settle thus limiting their full potential. Further, the surfactant used to emulsify is
considered to be undesirable.41
Despite the above-stated research efforts, oxygen transport remains one of the main
limitations in maintaining cell viability and functionality, thus requiring novel approaches
to deliver sufficient oxygen. The utility of zeolites for biomedical applications in not
new,27,

30, 33-36

but the idea that fluorinated zeolites could be used as oxygen vector in

tissue engineering is a novel concept. In this study, the fabrication of 3D porous PCU
scaffolds with uniformly embedded fluorinated zeolite particles with oxygen delivery
potential to cells is demonstrated. Furthermore, it is shown that the dissolved oxygen
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increased with increased fluorinated zeolite particles in water indicating that the oxygen
dissolving property of 1H, 1H, 2H, 2H-perfluorodecyltriethoxysilane was not affected by
chemically immobilizing to the zeolite framework. To enhance oxygen transport to
encapsulated cells, Roberts and coworkers suspended perfluorooctyl bromide and
perfluorotributylamine to alginate hydrogels as an oxygen vector.42,
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Although direct

comparison with the current study is not possible, their results suggest the perfluoro
compounds within hydrogel membrane improves effective oxygen diffusivity, ensuring
cell viability and functionality for the encapsulated spheres over extended culture times.

5.4 Conclusions
In this study, zeolite particles were successfully fluorinated as an oxygen vector using 1H,
1H, 2H, 2H-perfluorodecyltriethoxysilane for tissue engineering application. Dissolved
oxygen concentration significantly increased in the presence of fluorinated zeolite
particles. The fluorinated particles were then uniformly embedded into 3D polyurethane
scaffolds during the fabrication process. Vascular smooth muscle cell viability was not
affected by the presence of the fluorinated zeolite particles and; cell proliferation on
PCU-FZ scaffolds was significantly higher than the control PCU scaffolds. Cell
infiltration depths on PCU-FZ scaffolds was doubled compared with PCU scaffolds.
Taken together, these data suggest the potential of PCU-FZ scaffolds for tissue
engineering with enhanced oxygen delivery to cells.
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CHAPTER
6
6 GENERAL DISCUSSION AND CONCLUSIONS
Overview: This chapter provides a general summary of the overall work of this thesis
with specific objectives as mentioned in chapter 2. The strengths and limitations of the
work are also briefly summarized with few future work directions. Finally a brief
summary of the overall significance of vascular tissue engineering is included.

6.1 Summary

The main goal of this study was to increase the supply of oxygen to vascular
smooth muscle cell seeded on 3D PCU scaffolds. The initial step consisted of fabricating
3D porous PCU scaffolds using a pressure differential/particulate leaching technique.
NH4Cl was used as a porogen and different concentration of polymer dissolved in DMF
was used to fabricate disk and tubular shaped scaffolds. SEM micrographs were used to
characterize the structures and a diffusion apparatus was designed to measure the
effective diffusivity using of NeoFox oxygen sensor. The measured effective oxygen
diffusion coefficient and morphology of the scaffold was used to screen the best scaffold
for the work in this thesis. This helped for assessing scaffolds fabricated from different
concentrations of PCU for vascular tissue engineering applications. To improve the
adhesion of HCASMC on PCU scaffolds, scaffolds were modified by adsorbing
fibronectin on the surface of scaffold. HCASMC seeded scaffolds were cultured in both
static and flow conditions. Higher cell infiltration and proliferation were resulted in flow
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conditions than the static culture controls. This is likely due to an improved oxygen
supply by convective mass transfer in the cell-seed 3D PCU scaffolds.

PFD was used as an oxygen carrier because of its high oxygen solubility.
Significant increase in the dissolved oxygen was measured when 2% PFD was emulsified
in the culture media. Furthermore, PFD was found to have no toxicity and have no
morphological effect on HCASMCs.

This led us to use PFD as an oxygen carrier

molecule in the culture medium to improve the supply of oxygen to cell-seeded 3D PCU
scaffolds. Moreover, a better understanding could be obtained by modeling the oxygen
profile in the cell-seeded scaffold and in the lumen both at static and flow conditions with
and without oxygen carrier. Thus, a mathematical model was developed to simulate the
oxygen in the cell seeded 3D scaffolds.

Anther novel approach to improve the supply of oxygen to cell seeded 3D scaffold
was developed by embedding oxygen carrier particles into the scaffold. Micro size
Zeolite-Y particles were fluorinated using 1H, 1H, 2H, 2H-perfluorodecyltriethoxysilane
(PFES) and characterized. The surface characterization showed higher fluorine on the
surface of the particles. The surface modified particles significantly increased the
dissolved oxygen in the water at 37oC and had no toxicity to HACSMCs. The fluorinated
particles were successfully embedded into the skeleton of 3D PCU scaffold without any
modification to the morphology of the scaffold. Mercury porosimetry results confirmed
that the porosity and pore distribution of the scaffolds were not affected. A higher cell
proliferation and penetration depth were observed when HCASMC cultured on scaffolds
with embedded fluorinated Zeolite particle than HCASMC cultured on PCU control
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scaffolds. Thus an improvement on the supply of oxygen to cells seeded on 3D PCU
scaffolds was successfully achieved by embedding fluorinated particles as an oxygen
vector.
6.2 Strengths and limitations
In this study, three significant and equally important strategies of improving the
supply of oxygen to the cell seeded 3D scaffolds were demonstrated.1, 2 Previous studies
to improve the supply of oxygen mainly focused on scaffold materials and architecture.
For example, the use of polymeric hydrogels has been studied and shown to have an
improved supply of oxygen but week mechanical properties of hydrogels may preclude
practical applications.3-5 The use of polyurethane vascular grafts may overcome the
mechanical properties limitation. Moreover, the porous polyurethane scaffold constructs,
if fabricated from a non-degradable polyurethane, provide additional mechanical support,
therefore reducing the in vitro maturation time and avoiding problems associated with
polymer degradation.6, 7 Microfabrication and microfluidics approaches of fabrication 3D
scaffold showed improvements in the supply of oxygen but the fabrication methods were
limited to simple structures and, when it comes to tubular and cylindrical structures,
fabricating scaffolds with microfabrication approach becomes a complicated matter.8-10
Although, oxygen carriers and channeled scaffolds are reported to improve the supply of
oxygen,11-13 the practicality of channeling scaffolds with micro size spacing could reduce
the mechanical property. Furthermore, to supply sufficient oxygen, the spacing should be
very small which made it challenging to fabricate. The other strength of the study
documented in this thesis is the use of adult human coronary artery smooth muscle cells
which addresses the limitations related to species differences and unreliable data
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extrapolation from animal cell sources to humans. Given that smooth muscle cell
behavior is highly dependent on patient age and that elderly patients are in most need for
CABG, the use of adult cells best matches the clinical reality.

Amongst the significant contributions of this work is the use of diffusion chamber
to determine the effective diffusivity of scaffolds and use this parameter to screen the best
scaffold for vascular tissue engineering. Further significant contributions of this study are
the use of PFD as an oxygen carrier and the modeling of oxygen transfer with or without
oxygen carrier compounds.

Lastly, for the first time, inert Zeolite particles were

fluorinated and embedded into 3D scaffolds as an oxygen vector for tissue engineering. In
summation, this work improves the supply of oxygen to cell-seeded scaffolds using three
different strategies namely:
•

Convective mass transfer using a perfusion bioreactor,

•

Oxygen carrier molecule in the culture media and,

•

An oxygen vector embedded in the 3D scaffold

The main limitation of this study is that detailed histological studies and Western
blot analyses for dynamic and static cultures were not done. Due to time constraints some
studies of the dynamic cultures are also missing. Long-term maturation of the engineered
vascular graft will lead for successful fabrication of vascular constructs. Overall this
study attempted to solve one of limitation of tissue engineering which the supply of
oxygen to 3D constructs and added significant knowledge to the field.
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6.3 Future direction
This study sets the ground work for maturing vascular grafts in new and
automatically controlled perfusion bioreactors with improved oxygen supply. In addition
to flow conditions these bioreactors have to ability to simulate the physiological
environment by inducing mechanical stimulation and different kinds of pulsatile flows.
The load cells help to measure the applied forces like tensile, pulsatile and compression.
The use of a bioreactor will facilitate long-term culture to mature grafts, while promoting
cell distribution, cell proliferation, ECM synthesis and deposition, and tissue architecture.
Future work to fully explore the extent of proliferation of smooth muscle cells seeded
onto 3D polyurethane scaffolds, and the ability to switch phenotype in response to growth
factors and mechanical stimulation is strongly recommended. Future work should also
include the co-culture of endothelial cells and smooth muscle cells with different growth
factors and the effect of co-culture in cell differentiation, matrix deposition and behaviour
of smooth muscle cells at physiological conditions.

6.4 Significance
This study paves the way for the use of polyurethane scaffolds for fabricating
tissue-engineered vascular substitutes with improved oxygen supply. The fact that this
work was focused on vascular tissue engineering does not preclude the approach to be
equally applicable to other engineer tissue. In general, the strategies of improving the
supply of oxygen as documented in this thesis is anticipated to alleviate inhomogeneous
cell distribution and matrix deposition in 3D cultures and help maturing vascular grafts.
Matured tissue-engineered grafts have the potential to grow, self repair and self remodel
and these make them very attractive for the treatment of congenital anomalies in pediatric
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patients and atherosclerosis lesions in adults without immune-rejection. In addition to the
obvious clinical use, vascular tissue-engineered constructs can also be used as
pharmacological models to develop new drug candidates and test their toxicity and
efficacy.
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